Investment Agreement



 Exhibit 10.1 

 
 INVESTMENT AGREEMENT 

BY AND BETWEEN 
 ALPHATEC HOLDINGS, INC. 
 AND 

ECLIPSE ADVISORS, LLC 
 Dated 
 May 8, 2012 







 THIS INVESTMENT AGREEMENT is entered into as of the 8th day of May 2012 (this
“Agreement”), by and between ECLIPSE ADVISORS, LLC (“Investor”), and ALPHATEC HOLDINGS, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”). 

RECITALS 

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company may issue and sell to
the Investor and the Investor shall thereupon purchase from the Company up to $25,000,000 of newly issued shares of the Company’s common stock, $0.0001 par value (“Common Stock”); and 

WHEREAS, the offer and sale of the shares of Common Stock hereunder have been registered by the Company in the Registration
Statement, which has been declared effective by order of the Commission under the Securities Act. 
 NOW, THEREFORE, the
parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE I 

CERTAIN DEFINITIONS 

Section 1.1 Defined Terms. As used in this Agreement, the following terms shall have the following meanings specified or
indicated (such meanings to be equally applicable to both the singular and plural forms of the terms defined). 
 “Acceptable
Financing” shall have the meaning specified in Section 5.6(ii). 
 “Agreement” shall have the meaning specified in the
preamble hereof. 
 “ATM” shall have the meaning specified in Section 5.6(ii). 

“Base Prospectus” shall mean the Company’s prospectus, dated April 9, 2010, a preliminary form of which is included in the
Registration Statement, including the documents incorporated by reference therein. 
 “Below Market Offering” shall have the meaning
specified in Section 5.6(ii). 
 “Broker-Dealer” shall have the meaning specified in Section 5.13. 

“Bylaws” shall have the meaning set forth in Section 4.3. 
 “Cancellation Closing Date” shall mean the Closing Date described in clause (iii) of the definition of Closing Date. 
 “Cancellation Date” shall mean the date that a Cancellation Notice is deemed to be received by the Investor in accordance with Section 2.3. 







 “Cancellation Date Closing Adjusted Price” shall have the meaning specified in Section 2.4.

 “Cancellation Notice” shall mean a written notice from the Company to the Investor with respect to the cancellation of a Put
Notice. 
 “Charter” shall have the meaning set forth in Section 4.3. 
 “Closing” shall mean one of the closings of a purchase and sale of shares of Common Stock pursuant to Section 2.3. 
 “Closing Certificate” shall mean the closing certificate of the Company in the form of Exhibit C hereto. 
 “Closing Date” shall mean, with respect to a Closing, any of the following: (i) the 16th day following the Put Date related to such Closing, (ii) the 31st day following the Put Date related to such Closing or (iii) the
day following the Cancellation Date; or in each such case such other date as the Company and Investor shall agree; provided that all conditions to such Closing have been satisfied or waived on or before such applicable Closing Date. In the event
that a Closing Date falls on a day other than a Trading Day, then the Closing Date shall be the next succeeding Trading Day. 
 “Code”
shall mean the Internal Revenue Code of 1986, as amended. 
 “Commission” means the Securities and Exchange Commission. 

“Commitment Period” shall mean the period commencing on the Effective Date, and ending on the earlier of (i) the date on which Investor
shall have purchased Put Shares pursuant to this Agreement for an aggregate Purchase Price of the Maximum Commitment Amount, or (ii) the date occurring twenty four (24) months from the date of commencement of the Commitment Period.

 “Commitment Shares” shall have the meaning set forth in Section 9.1. 
 “Common Stock” shall have the meaning set forth in the preamble to this Agreement. 

“Company” shall have the meaning specified in the preamble to this Agreement. 
 “Current Market Price” shall mean, with respect to any particular measurement date, the closing price of a share of Common Stock as reported on the Principal Market for the Trading Day
immediately preceding such measurement date. 
 “Current Report” shall have the meaning set forth in Section 2.7. 

“Daily Trading Volume” in respect of a particular Trading Day means the daily trading volume of the Common Stock for that Trading Day on the
Principal Market as reported by Bloomberg, L.P. 







 “Disclosure Schedule” shall have the meaning set forth in the preamble to Article IV. 

“Dollar Amount Sold” shall have the meaning specified in Section 2.3. 
 “DTC” shall mean the Depository Trust Company. 
 “EDGAR” shall have the
meaning set forth in Section 4.3. 
 “Effective Date” shall mean the date of this Agreement. 

“Environmental Law” shall have the meaning specified in Section 4.15. 
 “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended. 

“Event Period” shall have the meaning specified in Section 7.2. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

“Exchange Cap” shall have the meaning specified in Section 6.2. 
 “FDA” shall have the meaning specified in Section 4.14(a). 
 “FINRA”
shall mean the Financial Industry Regulatory Authority, Inc. 
 “First Closing Date” shall mean the Closing Date described in clause
(i) in the definition of Closing Date. 
 “Floor Price” shall be the amount set forth in a Put Notice by the Company as the Floor
Price. 
 “GAAP” shall mean generally accepted accounting principles in the United States of America as applied by the Company.

 “Governmental Licenses” shall have the meaning specified in Section 4.14(a). 

“Indebtedness” shall have the meaning specified in Section 4.9. 
 “Integration Notice” shall have the meaning specified in Section 5.6(ii). 

“Intellectual Property” shall have the meaning specified in Section 4.14(b). 
 “Investment Amount” shall mean the dollar amount (within the range specified in Section 2.2) to be invested by Investor to purchase Put Shares with respect to any Put Notice as notified by
the Company to Investor in accordance with Section 2.2. 
 “Investor” shall have the meaning specified in the preamble to this
Agreement. 







 “Issuer Free Writing Prospectus” shall mean an “issuer free writing prospectus,” as
defined in Rule 433 promulgated under the Securities Act, relating to the Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i) under the Securities Act, in
each case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act. 

“Material Adverse Effect” shall mean any effect on the business, operations, properties, or financial condition of the Company that is material
and adverse to the Company and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with the ability of the Company to enter into and perform its obligations under this Agreement; provided, however, that
none of the following, individually or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred or insofar as reasonably can be foreseen would reasonably be expected to occur: (i) changes in
conditions in the United States or global capital, credit or financial markets generally, including changes in the availability of capital or currency exchange rates, provided such changes shall not have affected the Company in a materially
disproportionate manner as compared to other similarly situated companies; (ii) changes generally affecting the medical technology or biotechnology industries, provided such changes shall not have affected the Company in a materially
disproportionate manner as compared to other similarly situated companies; (iii) any effect of the announcement of this Agreement or the consummation of the transactions contemplated by this Agreement on the Company’s relationships,
contractual or otherwise, with customers, suppliers, vendors, bank or commercial lenders, lessors, collaboration partners, employees or consultants; (iv) the receipt of any notice that the Common Stock may be ineligible to continue listing or
quotation on the Principal Market, other than a final and non-appealable notice that the listing or quotation of the Common Stock on the Principal Market shall be terminated on a date certain; (v) any foreseeable deterioration in the business,
operations, properties or condition (financial or otherwise) of the Company and/or its Subsidiaries substantially resulting from (A) conditions or risks (including, without limitation, those contained in the section entitled “Risk
Factors” in the 2011 Form 10-K) existing as of the Effective Date that are specifically set forth in any of the SEC Documents or the Base Prospectus, (B) conditions or risks existing as of the date of any Prospectus Supplement that are
specifically set forth in such Prospectus Supplement or (C) any of the matters set forth in the Disclosure Schedule as of the Effective Date; and (vi) any decrease in the market price of the Common Stock (but excluding herefrom any
condition, occurrence, state of facts or event underlying such decrease to the extent that such condition, occurrence, state of facts or event otherwise would constitute a Material Adverse Effect). 

“Material Agreements” shall have the meaning specified in Section 4.16. 
 “Material Change in Ownership” shall mean the occurrence of any one or more of the following: (i) the acquisition by any person, including any syndicate or group deemed to be a
“person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of transactions, of shares of capital stock or other
securities of the Company entitling such person to exercise, upon an event of default or default or otherwise, 50% or more of the total voting power of all series and classes of capital stock and other securities of the Company entitled to vote
generally in the election of 







 
directors, other than any such acquisition by the Company, any Subsidiary or any employee benefit plan of the Company; (ii) any consolidation or merger of the Company with or into any other
person, any merger of another person into the Company, or any conveyance, transfer, sale, lease or other disposition of all or substantially all of the properties and assets of the Company to another person, other than (a) any such transaction
(x) that does not result in any reclassification, conversion, exchange or cancellation of outstanding shares of capital stock of the Company and (y) pursuant to which holders of capital stock of the Company immediately prior to such
transaction have the entitlement to exercise, directly or indirectly, 50% or more of the total voting power of all shares of capital stock of the Company entitled to vote generally in the election of directors of the continuing or surviving person
immediately after such transaction or (b) any merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into
shares of common stock of the surviving entity; (iii) during any consecutive two-year period, individuals who at the beginning of that two-year period constituted the Board of Directors (together with any new directors whose election to the
Board of Directors, or whose nomination for election by the stockholders of the Company, was approved by a vote of a majority of the directors then still in office who were either directors at the beginning of such period or whose elections or
nominations for election were previously so approved) cease for any reason to constitute a majority of the Board of Directors then in office; or (iv) the Company is liquidated or dissolved or a resolution is passed by the Company’s
stockholders approving a plan of liquidation or dissolution of the Company. Beneficial ownership shall be determined in accordance with Rule 13d-3 promulgated by the Commission under the Exchange Act. The term “person” shall include any
syndicate or group which would be deemed to be a “person” under Section 13(d)(3) of the Exchange Act. 
 “Maximum Commitment
Amount” shall mean Twenty Five Million Dollars ($25,000,000). 
 “Maximum Put Amount” shall mean, with respect to any Put, the
lower of (a) $5,000,000 or (b) (i) 700% multiplied by (ii)(A) the average of the Daily Trading Volume for the 30 Trading Days immediately preceding the Put Date multiplied by (B) the average of the VWAP for the 30
Trading Days immediately preceding the Put Date. 
 “Other Financing” shall have the meaning assigned to such term in
Section 5.6(ii) hereof. 
 “Other Financing Notice” shall have the meaning assigned to such term in Section 5.6(ii) hereof.

 “Permitted Free Writing Prospectus” shall have the meaning assigned to such term in Section 5.8(ii) hereof. 

“Restricted Period” shall have the meaning assigned to such term in Section 5.10(i) hereof. 

“Plan” shall have the meaning assigned to such term in Section 4.22 hereof. 
 “Price Reset Provision” shall have the meaning specified in Section 5.6(ii). 

“Pricing Period” shall mean (i) with respect to the First Closing Date, the period commencing on the first Trading Day following the Put
Date and ending on the Trading Day immediately preceding the First Closing Date, (ii) with respect to the Second Closing Date, the period 







 
commencing on the First Closing Date and ending on the day preceding the Second Closing Date and (iii) with respect to the Cancellation Closing Date shall mean (A) if the Cancellation
Closing Date precedes the First Closing Date, the period commencing on the Put Date and ending on the day immediately preceding the Cancellation Date or (B) if the Cancellation Closing Date is subsequent to the First Closing Date, the period
commencing on the First Closing Date and ending on the day immediately preceding the Cancellation Date. 
 “Principal Market” shall
mean the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the NYSE Euronext, the New York Stock Exchange, the OTC Bulletin Board or other trading exchange or market (or any successor to any of the foregoing),
whichever is at the time the principal trading exchange or market for the Common Stock. 
 “Prospectus” shall mean the Base
Prospectus, as supplemented by any Prospectus Supplement, including the documents incorporated by reference therein, together with any Permitted Free Writing Prospectus. 
 “Prospectus Supplement” shall mean any prospectus supplement to the Base Prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act, including the documents
incorporated by reference therein. 
 “Purchase Price” shall mean, with respect to any Put, 90% multiplied by the average of
the VWAP during the applicable Pricing Period or as otherwise provided in Section 2.4. 
 “Put” shall mean the right of the
Company to require the Investor to purchase shares of Common Stock, subject to the terms and conditions of this Agreement. 
 “Put
Date” shall mean any Trading Day during the Commitment Period that a Put Notice is deemed delivered pursuant to Section 2.2(b). 

“Put Notice” shall mean a written notice, substantially in the form of Exhibit A hereto, to Investor setting forth the Investment Amount with
respect to which the Company intends to require Investor to purchase shares of Common Stock pursuant to the terms of this Agreement. 

“Put Shares” shall mean all shares of Common Stock issued or issuable pursuant to a Put that has been exercised or may be exercised in
accordance with the terms and conditions of this Agreement. 
 “Reference Period” shall have the meaning specified in
Section 5.6(ii). 
 “Registrable Securities” shall mean the (a) Put Shares, (b) the Commitment Shares and (c) any
securities issued or issuable with respect to any of the foregoing by way of exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise.

 “Registration Statement” shall mean the registration statement on Form S-3, Commission File Number 333-164891, filed by the Company
with the Commission under the Securities Act for the registration of the Registrable Securities as such Registration Statement may be amended and 







 
supplemented from time to time (including any related registration statements filed pursuant to Rule 462(b) under the Securities Act), including all documents filed as part thereof or
incorporated by reference therein, and including all information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A, Rule 430B or Rule 430C under the Securities Act. 

“Restricted Period” shall have the meaning specified in Section 5.10. 
 “SEC Document” shall mean: (1) all reports, schedules, registrations, forms, statements, information and other documents filed by the Company with the Commission pursuant to the reporting
requirements of the Exchange Act, including all material filed pursuant to Section 13(a) or 15(d) of the Exchange Act, which have been filed by the Company since December 31, 2011 and which hereafter shall be filed by the Company during
the Commitment Period, including, without limitation, the Current Report and the Form 10-K filed by the Company for its fiscal year ended December 31, 2011 (the “2011 Form 10-K”), (2) the Registration Statement, as the same may
be amended from time to time, the Prospectus and each Prospectus Supplement, and each Permitted Free Writing Prospectus and (3) all information contained in such filings and all documents and disclosures that have been and heretofore shall be
incorporated by reference therein. 
 “Second Closing Adjusted Price” shall have the meaning specified in Section 2.4.

 “Second Closing Date” shall mean the Closing Date described in clause (ii) in the definition of Closing Date. 

“Securities Act” shall mean the Securities Act of 1933, as amended. 
 “Shares” shall mean the shares of Common Stock issuable by the Company to the Investor pursuant to this Agreement. 
 “Similar Financing” shall have the meaning specified in Section 5.6(ii). 

“SOXA” shall have the meaning specified in Section 4.6(c). 
 “Subsidiary” shall mean any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary voting power (absolutely or contingently) for
the election of directors or other persons performing similar functions are at the time owned directly or indirectly by the Company and/or any of its other Subsidiaries. 
 “Trading Day” shall mean a day on which the Principal Market shall be open for business. 

“Transaction Documents” shall mean this Agreement, the Exhibits hereto and the other documents and instruments deliverable pursuant hereto.

 “Transfer Agent” shall mean the transfer agent for the Common Stock (and to any substitute or replacement transfer agent for the
Common Stock upon the Company’s appointment of any such substitute or replacement transfer agent). 







 “VWAP” shall mean the daily volume weighted average price (based on a Trading Day from 9:30 a.m.
to 4:00 p.m. (New York time)) of the Company on the Principal Market as reported by Bloomberg Financial L.P. using the AQR function. 

“Warrant Value” shall mean the fair value of all warrants, options and other similar rights issued to a third party in connection with an Other
Financing, determined by using a standard Black-Scholes option-pricing model using an expected volatility percentage as shall be mutually agreed by the Investor and the Company. In the case of a dispute relating to such expected volatility
assumption, the Investor shall obtain applicable volatility data from three investment banking firms of nationally recognized reputation, and the parties hereto shall use the average thereof for purposes of determining the expected volatility
percentage in connection with the Black-Scholes calculation referred to in the immediately preceding sentence. 
 “2011 Form 10-K”
shall have the meaning specified in clause (1) of the definition of “SEC Document.” 
 ARTICLE II

 PURCHASE AND SALE OF COMMON STOCK 
 Section 2.1 Investments. Upon the terms and conditions set forth herein (including, without limitation, the provisions of Article VI), on any Put Date the Company may exercise a
Put by the delivery of a Put Notice. The number of Put Shares that Investor shall purchase pursuant to such Put shall be determined by dividing the Investment Amount specified in the Put Notice by the applicable Purchase Price(s) with respect to
such Put Notice. 
 Section 2.2 Delivery of Put Notice and Cancellation Notice. 

(a) Put Notice. At any time and from time to time during the Commitment Period, the Company may deliver a Put Notice
to Investor, subject to the conditions set forth herein; provided, however, that the Investment Amount identified in the applicable Put Notice shall not be greater than the Maximum Put Amount and, when taken together with any prior Put Notices,
shall not exceed the Maximum Commitment Amount. The Company shall not have the right to submit a Put Notice at anytime that there is an outstanding Put Notice. 
 (b) Date of Delivery of Put Notice. A Put Notice shall be deemed delivered on (i) the Trading Day it is received by facsimile or otherwise by Investor if such notice is received on
or prior to 12 noon New York time, or (ii) the immediately succeeding Trading Day if it is received by facsimile or otherwise by Investor after 12 noon New York time on a Trading Day or at anytime on a day which is not a Trading Day.

 (c) Date of Delivery of Cancellation Notice. A Cancellation Notice shall be deemed delivered on (i) the
Trading Day it is received by facsimile or otherwise by Investor if such notice is received on or prior to 10 a.m. New York time, or (ii) the immediately succeeding Trading Day if it is received by facsimile or otherwise by Investor after 10
a.m. New York time on a Trading Day or at any time on a day which is not a Trading Day. In the event that the 







 
Investor provides written notice to the Company of a designee to receive copies of the Cancellation Notice, then simultaneously with sending the Cancellation Notice to the Investor, the Company
shall send written notice to such designee. At the election of the Investor, the Cancellation Notice shall not be effective in the event that the Investor provides written notice of a designee to the Company and the Company does not simultaneously
provide the Cancellation Notice to such designee. 
 Section 2.3 Closings. 

(a) On the First Closing Date, the Company shall sell and the Investor shall purchase at the applicable Purchase Price the number of Put
Shares equal to 50% of the Investment Amount divided by the applicable Purchase Price. 
 (b) On the Second Closing Date,
the Company shall sell and the Investor shall purchase at the applicable Purchase Price the number of Put Shares equal to 50% of the Investment Amount divided by the applicable Purchase Price (subject to Section 2.4 below). 

(c) In the event that the Investor desires to purchase Put Shares on the Cancellation Closing Date, then on or before the Cancellation
Closing Date, the Investor shall provide written notice to the Company of the Closing together with the dollar amount of shares of Common Stock which the Investor has sold in accordance with the terms of this Agreement during the period commencing
on the later of the Put Date or the First Closing Date and ending on the day immediately preceding the Cancellation Date (“Dollar Amount Sold”). In such event on the Cancellation Closing Date, the Company shall sell and the Investor shall
purchase at the applicable Purchase Price the number of Put Shares equal to the Dollar Amount Sold (but in no event shall the Dollar Amount Sold be more than 50% of the Investment Amount for purposes of this sentence) divided by the
applicable Purchase Price or, if applicable under Section 2.4(b), the Cancellation Date Closing Adjusted Price. 
 (d) On
each Closing Date, the Company shall, or shall cause the Transfer Agent to, electronically transfer the Put Shares purchased by the Investor by crediting the Investor’s or its designees’ account at DTC through its Deposit/Withdrawal at
Custodian (DWAC) system, which Put Shares shall be freely tradable and transferable and without restriction on resale, against payment therefor to the Company’s designated account by wire transfer of immediately available funds upon the receipt
by the Investor of the Put Shares; provided that if the Put Shares are received by the Investor later than 1:00 p.m. (New York time), payment therefor shall be made with next day funds. As set forth in Section 2.6, a failure by the Company to
deliver such Put Shares shall result in the payment of liquidated damages by the Company to the Investor. Each of the Company and Investor shall deliver to each other all documents, instruments and writings required to be delivered or reasonably
requested by either of them pursuant to this Agreement in order to implement and effect the transactions contemplated herein. 

Section 2.4 Alternative Calculation of Purchase Price on the Second Closing Date and the Cancellation Closing Date. 

(a) In the event that the average of the VWAP for the Trading Days during the 30 








 
days following the Put Date is lower than the average of the VWAP for the Trading Days during the period commencing on the First Closing Date and ending on the Trading Day immediately preceding
the Second Closing Date, then (i) the Purchase Price on the Second Closing Date shall be equal to 90% of the average of the VWAP for the Trading Days during the 30 days following the Put Date (the “Second Closing Adjusted Price”) and
(ii) on the Second Closing Date the Company shall deliver to the Investor the number of Put Shares equal to: (i) the Investment Amount divided by the Second Closing Adjusted Price minus (ii) the number of Put Shares
issued to the Investor on the First Closing Date. 
 (b) In the event that the Cancellation Date occurs after the First
Closing Date, then this paragraph shall apply. In the event that the average of the VWAP for the period commencing on the Put Date and ending on the Trading Day immediately preceding the Cancellation Date is lower than the average of the VWAP for
the Trading Days during the period commencing on the First Cosing Date and ending on the Trading Day immediately preceding the Cancellation Date, then the Purchase Price on the Cancellation Closing Date shall be equal to 90% of the average of the
VWAP for the Trading Days commencing on the Put Date and ending on the Trading Day immediately preceding the Cancellation Date (the “Cancellation Date Closing Adjusted Price”). 

Section 2.5 Cancellation Notice. In the event that the VWAP for a Trading Day during the applicable Pricing Period is below the Floor
Price specified by the Company in the applicable Put Notice, then on or before the First Closing Date or the Second Closing Date, as the case may be, the Company may cancel and withdraw the Put Notice with respect to the shares of Common Stock to be
issued on such Closing Date; provided however, at the election of the Investor, the Investor shall have the right to purchase on the Cancellation Closing Date shares of Common Stock as set forth in Section 2.3(c). 

Section 2.6 Liquidated Damages. If the Company issues a Put Notice and fails to deliver the Put Shares to the Investor on the
applicable Closing Date pursuant to the terms of this Agreement and such failure continues for 10 Trading Days, the Company shall pay the Investor, in cash (or, at the option of the Investor, in shares of Common Stock which have not been registered
under the Securities Act valued at the applicable Purchase Price of the Put Shares failed to be delivered; provided that the issuance thereof by the Company would not violate the Securities Act or any applicable U.S. federal or state securities
laws), as liquidated damages for such failure and not as a penalty, an amount equal to 2.0% of the payment required to be paid by the Investor on such Closing Date for the initial 30 days following such Closing Date until such shares of Common Stock
have been delivered, and an additional 2.0% for each additional 30-day period thereafter until such shares of Common Stock have been delivered, which amount shall be prorated for such periods less than 30 days and all such issuances shall be subject
to the Exchange Cap. Nothing in this Section 2.6 shall be deemed to impair the rights of the Investor to compel specific performance by the Company of its obligations under this Agreement. 

Section 2.7 Current Report; Prospectus Supplement. As soon as practicable, but in any event not later than 5:30 p.m. (New York time)
on the first Trading Day immediately following the Effective Date, the Company shall file with the Commission (i) a report on Form 8-K relating to the transactions contemplated by, and describing the material terms and conditions of, this
Agreement (the “Current Report”), and (ii) a final Prospectus Supplement pursuant to Rule 424(b) under the Securities Act specifically relating to the transactions contemplated by, and








 
describing the material terms and conditions of, this Agreement, containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rule 430B
under the Securities Act, and disclosing all information relating to the transactions contemplated hereby required to be disclosed in the Registration Statement and the Prospectus, including, without limitation, information required to be disclosed
in the section captioned “Plan of Distribution” in the Prospectus. The Current Report shall include a copy of this Agreement as an exhibit and shall be incorporated by reference in the Registration Statement. The Company heretofore has,
provided (or will provide to) the Investor a reasonable opportunity to comment on a draft of such Current Report and Prospectus Supplement and has given (or will give) due consideration to such comments. Pursuant to Section 5.9 and subject to
the provisions of Section 5.8, on the first Trading Day immediately following the last Trading Day of the Pricing Period with respect to the Second Closing Date or the Cancellation Closing Date, as the case may be, the Company shall file with
the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act disclosing the total number of Shares to be issued and sold to the Investor thereunder, the total purchase price therefor and the net proceeds to be received by
the Company therefrom. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF INVESTOR 
 Investor represents and warrants to the
Company that: 
 Section 3.1 Organization and Standing of the Investor. The Investor is a limited liability company duly
organized, validly existing and in good standing under the laws of the State of New York. 
 Section 3.2 Authorization and
Power. The Investor has the requisite limited liability company power and authority to enter into and perform its obligations under this Agreement and to purchase the Put Shares in accordance with the terms hereof. The execution, delivery
and performance of this Agreement by the Investor and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary limited liability company action, and no further consent or authorization of the
Investor, or its members is required. This Agreement has been duly executed and delivered by the Investor. This Agreement constitutes a valid and binding obligation of the Investor enforceable against it in accordance with its terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies
or by other equitable principles of general application. 
 Section 3.3 No Conflicts. The execution, delivery and performance
by the Investor of this Agreement and the consummation by the Investor of the transactions contemplated herein do not and shall not (i) result in a violation of such Investor’s charter documents, bylaws or other applicable organizational
instruments, (ii) conflict with, constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material
agreement, mortgage, deed 







 
of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Investor is a party or is bound, (iii) create or impose any lien, charge or encumbrance on
any property of the Investor under any agreement or any commitment to which the Investor is party or under which the Investor is bound or under which any of its properties or assets are bound, or (iv) result in a violation of any federal,
state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any court or governmental agency applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case of clauses
(ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Investor to enter
into and perform its obligations under this Agreement in any material respect. The Investor is not required under federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or
registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or to purchase the Put Shares in accordance with the terms hereof. 

Section 3.4 Information. All materials relating to the business, financial condition, management and operations of the Company and
materials relating to the offer and sale of the Shares which have been requested by the Investor have been furnished or otherwise made available to the Investor or its advisors (subject to Section 5.12 of this Agreement). The Investor and its
advisors have been afforded the opportunity to ask questions of representatives of the Company. The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its
acquisition of the Shares. The Investor understands that it (and not the Company) shall be responsible for its own tax liabilities that may arise as a result of this investment or the transactions contemplated by this Agreement. The Investor is
aware of all of its obligations under U.S. federal and applicable state securities laws and all rules and regulations promulgated thereunder in connection with this Agreement and the transactions contemplated hereby and the purchase and sale of the
Shares. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
 Except as set forth in the
disclosure schedule delivered by the Company to the Investor (which is hereby incorporated by reference in, and constitutes an integral part of, this Agreement) (the “Disclosure Schedule”) or as set forth in the SEC Documents, the Company
hereby makes the following representations and warranties to the Investor: 
 Section 4.1 Organization, Good Standing and
Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power and authority to own, lease and operate its properties and assets and to
conduct its business as it is now being conducted as described in the SEC Documents. The Company and each Subsidiary is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the
business conducted or property owned by it makes such qualification necessary, except for any jurisdiction in which the failure to be so qualified would not have a Material Adverse Effect. 







 Section 4.2 Authorization, Enforcement. The Company has the requisite corporate power and
authority to enter into and perform this Agreement and to issue and sell the Put Shares in accordance with the terms hereof. Except for approvals of the Company’s Board of Directors or a committee thereof as may be required in connection with
any issuance and sale of Put Shares to the Investor hereunder (which approvals shall be obtained prior to the delivery of any Put Notice), the execution, delivery and performance by the Company of this Agreement and the consummation by it of the
transactions contemplated hereby have been duly and validly authorized by all necessary corporate action and no further consent or authorization of the Company or its Board of Directors or stockholders is required. This Agreement has been duly
executed and delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

Section 4.3 Capitalization. The authorized capital stock of the Company and the shares thereof issued and outstanding are as set forth
in the SEC Documents as of the dates reflected therein. All of the outstanding shares of Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable. Except as set forth in the SEC Documents, as of the Effective
Date, no shares of Common Stock were entitled to preemptive rights or registration rights and there were no outstanding options, warrants, scrip, rights to subscribe to, call or commitments of any character whatsoever relating to, or securities or
rights convertible into or exchangeable for, any shares of capital stock of the Company, other than those issued or granted in the ordinary course of business. Except as set forth in the SEC Documents, there were no contracts, commitments,
understandings, or arrangements by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, securities or rights convertible into or exchangeable for any shares of capital stock of the
Company, other than those issued or granted in the ordinary course of business. Except for customary transfer restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth in the SEC Documents, as of
the Effective Date, the Company was not a party to, and it had no knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except as set forth in the SEC Documents, the offer and sale of all
capital stock, convertible or exchangeable securities, rights, warrants or options of the Company issued prior to the Effective Date complied with all applicable federal and state securities laws, and no stockholder has any right of rescission or
damages or any “put” or similar right with respect thereto that would have a Material Adverse Effect. The Company has furnished or made available to the Investor via the Commission’s Electronic Data Gathering, Analysis and Retrieval
System (“EDGAR”) true and correct copies of the Company’s Certificate of Incorporation as in effect on the Effective Date (the “Charter”), and the Company’s Bylaws as in effect on the Effective Date (the
“Bylaws”). 
 Section 4.4 Issuance of Shares. The Put Shares to be issued under this Agreement have been or will be
duly authorized by all necessary corporate action and, when paid for or issued in accordance with the terms hereof, the Put Shares shall be validly issued and outstanding, fully paid and nonassessable, and, when the Put Shares have been issued to
the Investor, the Investor shall be entitled to all rights accorded to a holder and beneficial owner of Common Stock. 







 Section 4.5 No Conflicts. The execution, delivery and performance by the Company of this
Agreement and the consummation by the Company of the transactions contemplated herein will not (i) result in a violation of any provision of the Company’s Charter or Bylaws, (ii) conflict with, constitute a default (or an event which,
with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease
agreement, instrument or obligation to which the Company or any of its Subsidiaries is a party or is bound (including, without limitation, any listing agreement with a Principal Market), (iii) create or impose a lien, charge or encumbrance on
any property of the Company or any of its Subsidiaries under any agreement or any commitment to which the Company or any of its Subsidiaries is a party or under which the Company or any of its Subsidiaries is bound or under which any of their
respective properties or assets are bound, or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries or by which any property
or asset of the Company or any of its Subsidiaries are bound or affected, except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and
violations as would not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any
filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement, or to issue and sell the Shares to the Investor in accordance with the terms hereof (other than
any filings which may be required to be made by the Company with the Commission or its Principal Market subsequent to the Effective Date, including but not limited to a Prospectus Supplement under Sections 2.7 and 5.9 of this Agreement, and any
registration statement, prospectus or prospectus supplement which has been or may be filed pursuant to this Agreement). 
 Section 4.6
SEC Documents, Financial Statements. 
 (a) The Common Stock is registered pursuant to Section 12(b) or 12(g) of
the Exchange Act and, except as disclosed in the SEC Documents, as of the Effective Date the Company had timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act) all SEC Documents since
January 1, 2009. The Company has delivered or made available to the Investor via EDGAR or otherwise true and complete copies of the SEC Documents filed with the Commission prior to the Effective Date (including, without limitation, the 2011
Form 10-K) and has delivered or made available to the Investor via EDGAR or otherwise true and complete copies of all of the SEC Documents heretofore incorporated by reference in the Registration Statement and the Prospectus. The Company has not
provided to the Investor any information which, according to applicable law, rule or regulation, should have been disclosed publicly by the Company but which has not been so disclosed, other than with respect to the transactions contemplated by this
Agreement. As of its filing date, each SEC Document filed with the Commission and incorporated by reference in the Registration Statement and the Prospectus (including, without limitation, the 2011 Form 10-K) complied in all material respects with
the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it, and, as of its filing date (or, if amended or superseded by a filing prior to the Effective
Date, on the date of such amended or superseded filing), such SEC Document did not contain any untrue statement 







 
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. Each SEC Document to be filed with the Commission after the Effective Date and incorporated by reference in the Registration Statement, the Prospectus and any Prospectus Supplement required to be filed pursuant to Sections 2.7 and
5.9 hereof during the Commitment Period (including, without limitation, the Current Report), when such document becomes effective or is filed with the Commission, as the case may be, shall comply in all material respects with the requirements of the
Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it, and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (b) The financial statements, together with the related notes and schedules, of the Company included in the SEC Documents comply as to form in all material respects with all applicable accounting
requirements and the published rules and regulations of the Commission and all other applicable rules and regulations with respect thereto. Such financial statements, together with the related notes and schedules, have been prepared in accordance
with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not
include footnotes or may be condensed or summary statements and are subject to normal year-end audit adjustments), and fairly present in all material respects the financial condition of the Company and its consolidated Subsidiaries as of the dates
thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 
 (c) The Company has timely filed with the Commission and made available to the Investor via EDGAR or otherwise all certifications and statements required by (x) Rule 13a-14 or Rule 15d-14 under the
Exchange Act or (y) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002 (“SOXA”)) with respect to all relevant SEC Documents. The Company is in compliance in all material respects with the provisions of SOXA
applicable to it as of the date hereof. The Company maintains disclosure controls and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that all material information
concerning the Company and its Subsidiaries is made known on a timely basis to the individuals responsible for the timely and accurate preparation of the Company’s Commission filings and other public disclosure documents. As used in this
Section 4.6(c), the term “file” shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the Commission. 

(d) To the Company’s knowledge, Ernst & Young LLP, who has expressed their opinions on the audited financial statements and
related schedules included or incorporated by reference in the Registration Statement and the Base Prospectus are, with respect to the Company, independent public accountants as required by the Securities Act and are independent registered public
accounting firms within the meaning of SOXA as required by the rules of the Public Company Accounting Oversight Board. 







 Section 4.7 Subsidiaries. The 2011 Form 10-K sets forth each Subsidiary of the Company as
of the Effective Date, showing its jurisdiction of incorporation or organization, and the Company does not have any other Subsidiaries as of the Effective Date. 
 Section 4.8 No Material Adverse Effect. Since December 31, 2011, the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of
facts, condition or event which would have a Material Adverse Effect, except as disclosed in any SEC Documents filed since December 31, 2011. 
 Section 4.9 Indebtedness. The 2011 Form 10-K sets forth, as of December 31, 2011, all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which
the Company or any Subsidiary has commitments through such date. For the purposes of this Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of $2,000,000 (other than trade accounts
payable incurred in the ordinary course of business), (b) all guaranties, endorsements, indemnities and other contingent obligations in respect of Indebtedness of others in excess of $2,000,000, whether or not the same are or should be
reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of
any lease payments in excess of $2,000,000 due under leases required to be capitalized in accordance with GAAP. There is no existing or continuing default or event of default in respect of any Indebtedness of the Company or any of its Subsidiaries.

 Section 4.10 Title to Assets. Each of the Company and its Subsidiaries has good and marketable title to all of their
respective real and personal property reflected in the SEC Documents, free of mortgages, pledges, charges, liens, security interests or other encumbrances, except for those indicated in the SEC Documents or those that would not have a Material
Adverse Effect. To the Company’s knowledge, all real property leases of the Company are valid and subsisting and in full force and effect in all material respects. 
 Section 4.11 Actions Pending. There is no action, suit, claim, investigation or proceeding pending, or to the knowledge of the Company threatened in writing, against the Company or any
Subsidiary which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto or thereto. Except as set forth in the SEC Documents, there is no action, suit, claim, investigation
or proceeding pending, or to the knowledge of the Company threatened in writing, against or involving the Company, any Subsidiary or any of their respective properties or assets, or to the knowledge of the Company involving any officers or directors
of the Company or any of its Subsidiaries, including, without limitation, any securities class action lawsuit or stockholder derivative lawsuit, in each case which, if determined adversely to the Company, its Subsidiary or any officer or director of
the Company or its Subsidiaries, would have a Material Adverse Effect. 
 Section 4.12 Compliance with Law. The business of
the Company and the Subsidiaries has been and is presently being conducted in compliance with all applicable federal, state, local and foreign governmental laws, rules, regulations and ordinances, except as set forth in the SEC Documents and except
for such non-compliance which, individually or in the aggregate, would not have a Material Adverse Effect. 







 Section 4.13 Certain Fees. No brokers, finders or financial advisory fees or commissions
shall be payable by the Company or any Subsidiary (or any of their respective affiliates) with respect to the transactions contemplated by this Agreement. 
 Section 4.14 Operation of Business. 
 (a) To the
Company’s knowledge, the Company or one or more of its Subsidiaries possesses such permits, licenses, approvals, consents and other authorizations (including licenses, accreditation and other similar documentation or approvals of any local
health departments) (collectively, “Governmental Licenses”) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies, including, without limitation, the United States Food and Drug Administration
(“FDA”), necessary to conduct the business now operated by it, except where the failure to possess such Governmental Licenses, individually or in the aggregate, would not have a Material Adverse Effect. To the Company’s
knowledge, the Company and its Subsidiaries are in compliance with the terms and conditions of all such Governmental Licenses and all applicable FDA rules and regulations, guidelines and policies, and all applicable rules and regulations, guidelines
and policies of any governmental authority exercising authority comparable to that of the FDA (including any non-governmental authority whose approval or authorization is required under foreign law comparable to that administered by the FDA), except
where the failure to so comply, individually or in the aggregate, would not have a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the
failure of such Governmental Licenses to be in full force and effect, individually or in the aggregate, would not have a Material Adverse Effect. To the Company’s knowledge, as to each product that is subject to FDA regulation or similar
applicable legal provisions in any foreign jurisdiction that is developed, manufactured, tested, packaged, labeled, marketed, sold, distributed and/or commercialized by the Company or any of its Subsidiaries, each such product is being developed,
manufactured, tested, packaged, labeled, marketed, sold, distributed and/or commercialized in compliance with all applicable requirements of the FDA (and any non-governmental authority whose approval or authorization is required under foreign law
comparable to that administered by the FDA), including, but not limited to, those relating to investigational use, investigational device exemption, premarket notification, premarket approval, good clinical practices, good manufacturing practices,
record keeping, filing of reports, and patient privacy and medical record security, except where such non-compliance, individually or in the aggregate, would not have a Material Adverse Effect. To the Company’s knowledge, as to each product or
product candidate of the Company or any of its Subsidiaries subject to FDA regulation or similar legal provision in any foreign jurisdiction, all manufacturing facilities of the Company and its Subsidiaries are operated in compliance with the
FDA’s Quality System Regulation requirements at 21 C.F.R. Part 820, as applicable, except where such non-compliance, individually or in the aggregate, would not have a Material Adverse Effect. Except as set forth in the SEC Documents or the
Registration Statement, neither the Company nor any of its Subsidiaries has received any written notice of proceedings relating to the revocation or modification of any such Governmental Licenses or relating to a potential violation of, failure to
comply with, or request to produce additional information under, any FDA rules and regulations, guidelines or policies which, if the subject of any unfavorable decision, ruling or finding, individually or in the aggregate, would have a Material
Adverse Effect. Except as set forth in the SEC Documents or the Registration Statement, neither the Company nor any of its Subsidiaries has received any written 







 
correspondence, notice or request from the FDA that is of the nature that would be required to be set forth in the SEC Documents or the Registration Statement and has not been so set forth or
incorporated by reference therein, including, without limitation, written notice that any one or more products or product candidates of the Company or any of its Subsidiaries failed to receive approval from the FDA for use for any one or more
indications. This Section 4.14 does not relate to environmental matters, such items being the subject of Section 4.15. 
 (b) To the Company’s knowledge, the Company or one or more of its Subsidiaries owns or possesses adequate rights to use the patents, patent rights, licenses, inventions, copyrights, know-how
(including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, trade dress, logos, copyrights and other intellectual property, including,
without limitation, all of the intellectual property described in the SEC Documents as being owned or licensed by the Company (collectively, “Intellectual Property”), necessary to carry on the business now operated by it, except where
failure to own, license, or have such rights would not, individually or in the aggregate, have a Material Adverse Effect. Except as set forth in the SEC Documents, there are no actions, suits or judicial proceedings pending, or to the Company’s
knowledge threatened in writing, relating to patents or proprietary information to which the Company or any of its Subsidiaries is a party or of which any property of the Company or any of its Subsidiaries is subject, and neither the Company nor any
of its Subsidiaries has received any written notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any
Intellectual Property invalid or inadequate to protect the interest of the Company and its Subsidiaries therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy,
individually or in the aggregate, would have a Material Adverse Effect. 
 (c) To the Company’s knowledge, all clinical
trials conducted, supervised or monitored by, or on behalf of, the Company or any of its Subsidiaries have been conducted in compliance with all applicable federal, state, local and foreign laws, and the regulations and requirements of any
applicable governmental entity, including, but not limited to, FDA good clinical practice and good laboratory practice requirements (or, if applicable, the foreign equivalent requirements), except for such failure to comply that would not,
individually or in the aggregate, have a Material Adverse Effect. Except as set forth in the Registration Statement or the SEC Documents or as would not likely result in a Material Adverse Effect, neither the Company nor any of its Subsidiaries has
received any written notices or correspondence from the FDA or any other governmental agency requiring the termination, suspension, delay or modification of any pre-clinical or clinical trials conducted by, or on behalf of, the Company or any of its
Subsidiaries or in which the Company or any of its Subsidiaries has participated that are described in the Registration Statement or the SEC Documents, if any, or the results of which are referred to in the Registration Statement or the SEC
Documents. To the Company’s knowledge, all clinical trials previously conducted by, or on behalf of, the Company or any of its Subsidiaries while conducted by or on behalf of the Company or any of its Subsidiaries, were conducted in material
compliance with all applicable federal, state, local and foreign laws, and the regulations and requirements of any applicable governmental entity, including, but not limited to, FDA good clinical practice and good laboratory practice requirements
(or, if applicable, the foreign equivalent requirements) , except for such failure to comply that would not, individually or in the aggregate, have a Material Adverse Effect. 







 Section 4.15 Environmental Compliance. To the Company’s knowledge and except as
disclosed in the SEC Documents, the Company and each of its Subsidiaries have obtained all material approvals, authorization, certificates, consents, licenses, orders and permits or other similar authorizations of all governmental authorities, or
from any other person, that are required under any Environmental Laws, except for any approvals, authorization, certificates, consents, licenses, orders and permits or other similar authorizations the failure of which to obtain does not or would not
have a Material Adverse Effect. “Environmental Laws” shall mean all applicable laws relating to the protection of the environment including, without limitation, all requirements pertaining to reporting, licensing, permitting, controlling,
investigating or remediating emissions, discharges, releases or threatened releases of hazardous substances, chemical substances, pollutants, contaminants or toxic substances, materials or wastes, whether solid, liquid or gaseous in nature, into the
air, surface water, groundwater or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of hazardous substances, chemical substances, pollutants, contaminants or toxic substances,
material or wastes, whether solid, liquid or gaseous in nature. Except for such instances as would not, individually or in the aggregate, have a Material Adverse Effect, to the Company’s knowledge, there are no past or present events,
conditions, circumstances, incidents, actions or omissions relating to or in any way affecting the Company or its Subsidiaries that violate or would reasonably be expected to violate any Environmental Law after the Effective Date or that would
reasonably be expected to give rise to any environmental liability, or otherwise form the basis of any claim, action, demand, suit, proceeding, hearing, study or investigation (i) under any Environmental Law, or (ii) based on or related to
the manufacture, processing, distribution, use, treatment, storage (including without limitation underground storage tanks), disposal, transport or handling, or the emission, discharge, release or threatened release of any hazardous substance.

 Section 4.16 Material Agreements. Except as set forth in the SEC Documents, neither the Company nor any Subsidiary of the
Company is a party to any written or oral contract, instrument, agreement commitment, obligation, plan or arrangement, a copy of which would be required to be filed with the Commission as an exhibit to an annual report on Form 10-K (collectively,
“Material Agreements”). Except as set forth in the SEC Documents, the Company and each of its Subsidiaries have performed in all material respects all the obligations required to be performed by them under the Material Agreements, have
received no written notice of default or an event of default by the Company or any of its Subsidiaries thereunder and are not aware of any basis for the assertion thereof, and neither the Company or any of its Subsidiaries nor, to the knowledge of
the Company, any other contracting party thereto are in default under any Material Agreement now in effect, the result of which would have a Material Adverse Effect. Except as set forth in the SEC Documents, each of the Material Agreements is in
full force and effect, and constitutes a legal, valid and binding obligation enforceable in accordance with its terms against the Company and/or any of its Subsidiaries and, to the knowledge of the Company, each other contracting party thereto,
except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights
and remedies or by other equitable principles of general application. 
 Section 4.17 Transactions With Affiliates. Except as
set forth in the SEC Documents, there are 







 
no loans, leases, agreements, contracts, royalty agreements, management contracts, service arrangements or other continuing transactions exceeding $120,000 between (a) the Company or any
Subsidiary, on the one hand, and (b) any person or entity who would be covered by Item 404(a) of Regulation S-K, on the other hand. Except as disclosed in the SEC Documents, there are no outstanding amounts payable to or receivable from,
or advances by the Company or any of its Subsidiaries to, and neither the Company nor any of its Subsidiaries is otherwise a creditor of or debtor to, any beneficial owner of more than 5% of the outstanding shares of Common Stock, or any director,
employee or affiliate of the Company or any of its Subsidiaries, other than (i) reimbursement for reasonable expenses incurred on behalf of the Company or any of its Subsidiaries or (ii) as part of the normal and customary terms of such
persons’ employment or service as a director with the Company or any of its Subsidiaries. 
 Section 4.18 Securities Act; FINRA
Rules. The Company has complied with all applicable federal and state securities laws in connection with the offer, issuance and sale of the shares of Common Stock hereunder. The Company has prepared and filed with the Commission in
accordance with the provisions of the Securities Act the Registration Statement, including a base prospectus relating to the shares of Common Stock issuable hereunder. The Registration Statement was declared effective by order of the Commission on
April 9, 2010. As of the date hereof, no stop order suspending the effectiveness of the Registration Statement has been issued by the Commission or is continuing in effect under the Securities Act and no proceedings therefor are pending before
or, to the Company’s knowledge, threatened by the Commission. No order preventing or suspending the use of the Prospectus or any Permitted Free Writing Prospectus has been issued by the Commission. As of the Effective Date, the Company
satisfies the requirements for the use of Form S-3 under the Securities Act for the offering and sale of the Shares contemplated by this Agreement (without reliance on General Instruction I.B.6. of Form S-3). If, during the term of this Agreement,
the Company becomes subject to General Instruction I.B.6. of Form S-3, the Company hereby confirms that, for as long as the Company is subject to General Instruction I.B.6. of Form S-3 during the term of this Agreement, the Company shall not offer
or sell any securities in reliance on General Instruction I.B.6. of Form S-3 to the extent the aggregate market value of such securities, when aggregated with the aggregate market value of all of the shares of Common Stock that have been sold
pursuant to this Agreement in the 12 calendar months immediately prior to and including such sale in reliance on General Instruction I.B.6. of Form S-3, exceeds the aggregate market value limitations imposed by General Instruction I.B.6 of Form S-3,
calculated in accordance with Instructions 1 and 2 to General Instruction I.B.6 of Form S-3. The Company is not, and has not previously been at any time, a “shell company” (as such term is defined in Rule 405 under the Securities Act). The
Commission has not notified the Company of any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(1) under the Securities Act. The Registration Statement complied in all material respects on the date on which it
was declared effective by the Commission, and will comply in all material respects, at each deemed effective date with respect to the Investor pursuant to Rule 430B(f)(2) of the Securities Act, with the requirements of the Securities Act, and the
Registration Statement (including the documents incorporated by reference therein) did not on the date it was declared effective by the Commission, and shall not at each deemed effective date with respect to the Investor pursuant to Rule 430B(f)(2)
of the Securities Act, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided that this representation and warranty does not
apply to statements in or omissions from 







 
the Registration Statement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use
therein. The Registration Statement, as of the Effective Date, meets the requirements set forth in Rule 415(a)(1)(x) under the Securities Act. The Base Prospectus complied in all material respects on its date and on the Effective Date, and will
comply in all material respects on each applicable Put Date and, when taken together with the applicable Prospectus Supplement and any applicable Permitted Free Writing Prospectus, on each applicable Closing Date, with the requirements of the
Securities Act and did not on its date and on the Effective Date and shall not on each applicable Closing Date and, when taken together with the applicable Prospectus Supplement and any applicable Permitted Free Writing Prospectus, on each
applicable Closing Date contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, that this representation and warranty does not apply to statements in or omissions from the Registration Statement, Base Prospectus, Propsoectus Supplement or Permitted Free Writing Prospectus made in reliance upon and in
conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. 
 (iii) The offering of the shares of Common Stock pursuant to this Agreement qualifies for the exemption from the filing requirements of Rule 5110 of FINRA afforded by FINRA Rule 5110(b)(7)(C)(i).

 (iv) Each Prospectus Supplement required to be filed pursuant to Sections 2.7 and 5.9 hereof, when taken together with the
Base Prospectus and any applicable Permitted Free Writing Prospectus, on its date and on the applicable Closing Date, shall comply in all material respects with the provisions of the Securities Act and shall not on its date and on the applicable
Closing Date contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading,
except that this representation and warranty does not apply to statements in or omissions from any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on
behalf of the Investor expressly for use therein. 
 (v) At the earliest time after the filing of the Registration Statement
that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) relating to the Put Shares, the Company was not and is not an “ineligible issuer” (as defined in Rule
405 under the Securities Act). Each Permitted Free Writing Prospectus (a) shall conform in all material respects to the requirements of the Securities Act on the date of its first use, (b) when considered together with the Prospectus on
each applicable Put Date and on each applicable Closing Date, shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they are made, not misleading, and (c) shall not include any information that conflicts with the information contained in the Registration Statement, including any document incorporated by reference therein and any
Prospectus Supplement deemed to be a part thereof that has not been superseded or modified. The immediately preceding sentence does not apply to statements in or omissions from any Permitted Free Writing Prospectus made in reliance upon and in
conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. 







 (vi) Prior to the Effective Date, the Company has not distributed any offering material in
connection with the offering and sale of the Shares. From and after the Effective Date and prior to the completion of the distribution of the Shares, the Company shall not distribute any offering material in connection with the offering and sale of
the Shares, other than the Registration Statement, the Base Prospectus as supplemented by any Prospectus Supplement or a Permitted Free Writing Prospectus. 
 Section 4.19 Employees. As of the Effective Date, other than with respect to the collective bargaining agreements in place for Scient’x SAS and Surgiview SAS, neither the Company
nor any Subsidiary of the Company has any collective bargaining arrangements or agreements covering any of its employees, except as set forth in the SEC Documents. As of the Effective Date, except as disclosed in the Registration Statement or the
SEC Documents, no officer, consultant or key employee of the Company or any Subsidiary whose termination, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, has terminated or, to the knowledge of
the Company, has any present intention of terminating his or her employment or engagement with the Company or any Subsidiary. 

Section 4.20 Use of Proceeds. The proceeds from the sale of the Shares shall be used by the Company and its Subsidiaries as set forth
in the Base Prospectus and any Prospectus Supplement filed pursuant to Sections 2.7 and 5.9. 
 Section 4.21 Investment Company Act
Status. The Company is not, and as a result of the consummation of the transactions contemplated by this Agreement and the application of the proceeds from the sale of the Put Shares as set forth in the Base Prospectus and any Prospectus
Supplement shall not be, an “investment company” or a company “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended. 

Section 4.22 ERISA. No liability to the Pension Benefit Guaranty Corporation has been incurred with respect to any Plan by the Company
or any of its Subsidiaries which has had or would have a Material Adverse Effect. No “prohibited transaction” (as defined in Section 406 of ERISA or Section 4975 of the Code) or “accumulated funding deficiency” (as
defined in Section 203 of ERISA) or any of the events set forth in Section 4043(b) of ERISA has occurred with respect to any Plan which has had or would have a Material Adverse Effect, and the execution and delivery of this Agreement and
the issuance and sale of the Shares hereunder shall not result in any of the foregoing events. Each Plan is in compliance in all material respects with applicable law, including ERISA and the Code; the Company has not incurred and does not expect to
incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any Plan; and each Plan for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code is so
qualified in all material respects and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualifications. As used in this Section 4.22, the term “Plan” shall mean an “employee pension
benefit plan” (as defined in Section 3 of ERISA) which is or has been established or maintained, or to which contributions are or have been made, by the Company or any Subsidiary or by any trade or business, whether or not incorporated,
which, together with the Company or any Subsidiary, is under common control, as described in Section 414(b) or (c) of the Code. 







 Section 4.23 Taxes. The Company (i) has filed all necessary federal, state and
foreign income and franchise tax returns or has duly requested extensions thereof, except for those the failure of which to file would not have a Material Adverse Effect, (ii) has paid all federal, state, local and foreign taxes due and payable
for which it is liable, except to the extent that any such taxes are being contested in good faith and by appropriate proceedings, except for such taxes the failure of which to pay would not have a Material Adverse Effect, and (iii) does not
have any tax deficiency or claims outstanding or assessed or, to the Company’s knowledge, proposed against it which would have a Material Adverse Effect. 
 Section 4.24 Insurance. The Company carries, or is covered by, insurance in such amounts and covering such risks as the Company deems is adequate for the conduct of its and its
Subsidiaries’ businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. 
 Section 4.25 Acknowledgement Regarding Investor’s Purchase of Shares. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm’s length
purchaser with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
this Agreement and the transactions contemplated hereunder, and any advice given by the Investor or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereunder is merely incidental to the
Investor’s purchase of the Put Shares. 
 ARTICLE V 

COVENANTS 

The Company covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for
the benefit of the other party, during the Commitment Period: 
 Section 5.1 Securities Compliance. The Company shall notify
the Principal Market, as necessary, in accordance with its rules and regulations, of the transactions contemplated by this Agreement, and shall take all necessary action, undertake all proceedings and obtain all registrations, permits, consents and
approvals for the legal and valid issuance of the Shares to the Investor in accordance with the terms of this Agreement. 
 Section 5.2
Registration and Listing. The Company shall take all reasonable actions necessary to cause the Common Stock to continue to be registered as a class of securities under Sections 12(b) or 12(g) of the Exchange Act, shall comply with its
reporting and filing obligations under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities Act) to terminate or suspend such registration or to terminate or suspend its reporting and
filing obligations under the Exchange Act or Securities Act, except as permitted herein. The Company shall take all action reasonably necessary to continue the listing and trading of its Common Stock and the listing of the Put Shares purchased by
Investor hereunder on the Principal Market (including, without limitation, maintaining sufficient tangible net assets), 







 
and shall comply with the Company’s reporting, filing and other obligations under the bylaws, listed securities maintenance standards and other rules and regulations of FINRA and the
Principal Market. 
 Section 5.3 Compliance with Laws. 

(i) The Company shall comply, and cause each Subsidiary to comply, (a) with all laws, rules, regulations and orders applicable to
the business and operations of the Company and its Subsidiaries except as would not have a Material Adverse Effect and (b) with all applicable provisions of the Securities Act, the Exchange Act, the rules and regulations of FINRA and the
listing standards of the Principal Market except as would not have a Material Adverse Effect. Without limiting the generality of the foregoing, neither the Company nor any of its officers, directors or affiliates has taken or will take, directly or
indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, or which would in the future reasonably be expected to cause or result in, stabilization or manipulation
of the price of any security of the Company. 
 (ii) The Investor shall comply with all laws, rules, regulations and orders
applicable to the performance by it of its obligations under this Agreement and its investment in the shares of Common Stock issued to the Investor pursuant to this Agreement, except as would not, individually or in the aggregate, prohibit or
otherwise interfere with the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect. Without limiting the foregoing, the Investor shall comply with all applicable provisions of the Securities
Act and the Exchange Act. 
 Section 5.4 Keeping of Records and Books of Account; Foreign Corrupt Practices Act. 

(i) The Company shall keep and cause each Subsidiary to keep adequate records and books of account, in which complete entries shall be
made in accordance with GAAP consistently applied, reflecting all financial transactions of the Company and its Subsidiaries, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization, taxes, bad
debts and other purposes in connection with its business shall be made. The Company shall maintain a system of internal accounting controls that (a) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect
the transactions and dispositions of the assets of the Company; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and
expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of the Company’s assets that would likely have a material effect on the Company’s financial statements. 

(ii) Neither the Company, nor any of its Subsidiaries, nor to the knowledge of the Company, any of their respective directors, officers,
agents, employees or any other persons acting on their behalf shall, in connection with the operation of the Company’s and its Subsidiaries’ respective businesses, (a) use any corporate funds for unlawful contributions, payments,
gifts or entertainment or to make any unlawful expenditures relating to political activity to government officials, candidates or members of political parties or organizations, 







 
(b) pay, accept or receive any unlawful contributions, payments, expenditures or gifts, or (c) violate or operate in noncompliance with any export restrictions, anti-boycott
regulations, embargo regulations or other applicable domestic or foreign laws and regulations, in each case, except for such items that would not likely result in a Material Adverse Effect. 

(iii) Subject to the requirements of Section 5.12 of this Agreement, from time to time, from and after the period beginning with the
Put Date through and including the applicable Closing Date, the Company shall make available for inspection and review by the Investor, customary documentation allowing the Investor and/or its appointed counsel or advisors to conduct due diligence.

 Section 5.5 Limitations on Holdings and Issuances. Notwithstanding any other provision of this Agreement, the Company
shall not be obligated to issue and the Investor shall not purchase any shares of Common Stock which, when aggregated with all other shares of Common Stock then beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act and
Rule 13d-3 promulgated thereunder) by the Investor and its affiliates, would result in the beneficial ownership by the Investor of more than 4.9% of the then issued and outstanding shares of Common Stock. 

Section 5.6 Other Agreements and Other Financings. 
 (i) The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict
with or impair the ability or right of the Company or any Subsidiary to perform its obligations under this Agreement in connection with a previously provided Put Notice or the settlement thereof, including, without limitation, the obligation of the
Company to deliver Put Shares to the Investor in respect of a previously provided Put Notice on the applicable Closing Date. 

(ii) If the Company enters into any agreement, plan, arrangement or transaction with a third party or seeks to utilize any existing
agreement, plan or arrangement with a third party, in each case the principal purpose of which is to implement, effect or consummate, at any time during the period beginning on the first Trading Day of any Pricing Period and ending on the second
Trading Day next following the applicable Closing Date (the “Reference Period”), a financing (an “Other Financing”) that does not constitute an Acceptable Financing, the Company shall provide prompt notice thereof (an “Other
Financing Notice”) to the Investor; provided, however, that such Other Financing Notice must be received by the Investor not later than the earlier of (a) 48 hours after the Company’s execution of any agreement, plan, arrangement or
transaction relating to such Other Financing (or, with respect to any existing agreement, plan or arrangement, 48 hours after the Company has determined to utilize any such existing agreement, plan or arrangement to implement, effect or consummate
such Other Financing) and (b) the second Trading Day immediately preceding the applicable Closing Date with respect to the applicable Put Notice; provided, further, that the Company shall notify the Investor within 24 hours (an
“Integration Notice”) if it enters into any agreement, plan, arrangement or transaction with a third party, the principal purpose of which is to obtain at any time during the Commitment Period an Other Financing which would be aggregated
with the transactions contemplated by this Agreement for purposes of determining whether approval of the Company’s stockholders is required under any by-law, listed securities maintenance standards or other rules of the Principal








 
Market and, if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules and regulations of the Principal Market,
the Company shall publicly disclose such information in accordance with Regulation FD and the applicable rules and regulations of the Principal Market. For purposes of this Section 5.6(ii), any press release issued by, or SEC Document filed or
furnished by, the Company shall constitute sufficient notice, provided, that it is issued, filed or furnished, as the case may be, within the time requirements set forth in the first sentence of this Section 5.6(ii) for an Other Financing
Notice or an Integration Notice, as applicable. For greater certainty, the entry by the Company into any agreement, plan, arrangement or transaction with a third party to obtain an Other Financing (or any other financing) outside of a Pricing Period
shall not trigger any requirement for the Company to deliver an Other Financing Notice (it being acknowledged and agreed that nothing contained in this Section 5.6(ii) shall limit or modify in any respect the Company’s obligations in
Section 7.2). With respect to any Pricing Period for which the Company is required to provide an Other Financing Notice pursuant to the first sentence (including the provisos thereto) of this Section 5.6(ii), the Investor shall have the
option to purchase the Put Shares subject to the Put Notice at (x) the price therefor in accordance with the terms of this Agreement or (y) the third party’s per share purchase price in connection with the Other Financing, net of such
third party’s discounts, Warrant Value and fees. An “Other Financing” shall mean (w) the issuance of Common Stock for a purchase price less than, or the issuance of securities convertible into or exchangeable for Common Stock at
an exercise or conversion price (as the case may be) less than, the then Current Market Price of the Common Stock (including, without limitation, pursuant to any “equity line” or other financing that is substantially similar to the
financing provided for under this Agreement, or pursuant to any other transaction in which the purchase, conversion or exchange price for such Common Stock is determined using a floating discount or other post-issuance adjustable discount to the
then Current Market Price (any such transaction, a “Similar Financing”)), in each case, after all fees, discounts, Warrant Value and commissions associated with the transaction (a “Below Market Offering”); (x) an
“at-the-market” offering of Common Stock or securities convertible into or exchangeable for Common Stock pursuant to Rule 415(a)(4) under the Securities Act (an “ATM”); (y) the implementation by the Company of any mechanism
in respect of any securities convertible into or exchangeable for Common Stock for the reset of the purchase price of the Common Stock to below the then Current Market Price of the Common Stock (including, without limitation, any antidilution or
similar adjustment provisions in respect of any Company securities, but specifically excluding customary adjustments for stock splits, stock dividends, stock combinations and similar events) (a “Price Reset Provision”); or (z) the
issuance of options, warrants or similar rights of subscription, in each case not constituting an Acceptable Financing. “Acceptable Financing” shall mean the issuance by the Company of: (1) debt securities or any class or series of
preferred stock of the Company, in each case that are not convertible into or exchangeable for Common Stock or securities convertible into or exchangeable for Common Stock; (2) shares of Common Stock or securities convertible into or
exchangeable for Common Stock (including, without limitation, convertible debt securities) other than in connection with a Below Market Offering or an ATM; (3) shares of Common Stock or securities convertible into or exchangeable for Common
Stock (including, without limitation, convertible debt securities) in connection with an underwritten public offering of securities of the Company or a registered direct public offering of securities of the Company, in each case where the price per
share of such Common Stock (or the conversion or exercise price of such securities, 







 
as applicable) is fixed concurrently with the execution of definitive documentation relating to such offering and the issuance of shares of Common Stock upon the conversion, exercise or exchange
thereof; (4) shares of Common Stock or securities convertible into or exchangeable for Common Stock or similar rights in connection with awards under the Company’s benefit and equity plans and arrangements or shareholder rights plan or
pursuant to consulting or other vendor agreements and the issuance of shares of Common Stock upon the conversion, exercise or exchange thereof; (5) shares of Common Stock issuable upon the exercise, conversion or exchange of equity awards or
convertible, exercisable or exchangeable securities (including, without limitation, convertible debt securities) outstanding as of the Effective Date; (6) shares of Common Stock or securities convertible into or exchangeable for Common Stock
(including, without limitation, convertible debt securities) issued in connection with the acquisition, license or sale of one or more other companies, equipment, technologies or lines of business, and the issuance of shares of Common Stock upon the
conversion, exercise or exchange thereof; (7) shares of Common Stock or securities convertible into or exchangeable for Common Stock (including, without limitation, convertible debt securities) or similar rights to subscribe for the purchase of
shares of Common Stock in connection with technology sharing, licensing, research, marketing, manufacturing, supply, joint development agreements or similar strategic or collaborative agreements or arrangements (or amendments thereto) with third
parties, and the issuance of shares of Common Stock upon the conversion, exercise or exchange thereof; and (8) shares of Common Stock and/or warrants or similar rights to subscribe for the purchase of shares of Common Stock issued in connection
with commercial credit arrangements, equipment financings and/or real property leases or service agreements (or amendments thereto) and the issuance of shares of Common Stock upon the exercise thereof. 

Section 5.7 Stop Orders. The Company shall advise the Investor promptly (but in no event later than 24 hours) and shall confirm such
advice in writing: (i) of the Company’s receipt of notice of any request by the Commission for amendment of or a supplement to the Registration Statement, the Prospectus, any Permitted Free Writing Prospectus or for any additional
information; (ii) of the Company’s receipt of notice of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus
Supplement, or of the suspension of qualification of the any shares of Common Stock issuable hereunder for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the
Company becoming aware of the happening of any event, which makes any statement of a material fact made in the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus untrue or which requires the making of any additions to or
changes to the statements then made in the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the
statements then made therein (in the case of the Prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend the Registration Statement or supplement the Prospectus or any Permitted Free Writing
Prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investor the substance or specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately
preceding sentence, but rather, shall only be required to disclose that the event has occurred. The Company shall not issue a Put Notice during the continuation of any of the foregoing events. If at any time the Commission shall issue any stop order
suspending the 







 
effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement, the Company shall use commercially reasonable efforts to obtain
the withdrawal of such order at the earliest possible time. 
 Section 5.8 Amendments to the Registration Statement; Prospectus
Supplements; Free Writing Prospectuses. 
 (i) Except as provided in this Agreement and other than reports required to
be filed pursuant to the Exchange Act, the Company shall not file with the Commission any amendment to the Registration Statement that relates to the Investor, the Agreement or the transactions contemplated hereby or file with the Commission any
Prospectus Supplement that relates to the Investor, this Agreement or the transactions contemplated hereby with respect to which (a) the Investor shall not previously have been advised, (b) the Company shall not have given due
consideration to any comments thereon received from the Investor or its counsel, or (c) the Investor shall reasonably object after being so advised, unless the Company reasonably has determined that it is necessary to amend the Registration
Statement or make any supplement to the Prospectus to comply with the Securities Act or any other applicable law or regulation, in which case the Company shall promptly (but in no event later than 24 hours) so inform the Investor, the Investor shall
be provided with a reasonable opportunity to review and comment upon any disclosure relating to the Investor and the Company shall expeditiously furnish to the Investor an electronic copy thereof. In addition, for so long as, in the reasonable
opinion of counsel for the Investor, the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required to be delivered in connection with any purchase or sale of shares of Common Stock by the Investor,
the Company shall not file any Prospectus Supplement with respect to the Shares without delivering or making available a copy of such Prospectus Supplement, together with the Base Prospectus, to the Investor promptly. 

(ii) The Company has not made, and agrees that unless it obtains the prior written consent of the Investor it will not make, an offer
relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company or the Investor with the Commission or retained by the Company or the
Investor under Rule 433 under the Securities Act. The Investor has not made, and agrees that unless it obtains the prior written consent of the Company it will not make, an offer relating to the shares of Common Stock that would constitute a Free
Writing Prospectus required to be filed by the Company with the Commission or retained by the Company under Rule 433 under the Securities Act. Any such Issuer Free Writing Prospectus or other Free Writing Prospectus consented to by the Investor or
the Company is referred to in this Agreement as a “Permitted Free Writing Prospectus.” The Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing
Prospectus and (y) it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 under the Securities Act applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the
Commission, legending and record keeping. 
 Section 5.9 Prospectus Delivery. The Company shall file with the Commission a
Prospectus Supplement pursuant to Rule 424(b) under the Securities Act on the first Trading Day immediately following the last Trading Day of the Pricing Period with respect to the Second Closing Date or the Cancellation Closing Date, as the case
may be. The Company shall provide the Investor a reasonable opportunity to comment on a draft of each such Prospectus Supplement 







 
and any Issuer Free Writing Prospectus, shall give due consideration to all such comments and, subject to the provisions of Section 5.8 hereof, shall deliver or make available to the
Investor, without charge, an electronic copy of each form of Prospectus Supplement, together with the Base Prospectus, and any Permitted Free Writing Prospectus on each applicable Closing Date. The Company consents to the use of the Prospectus (and
of any Prospectus Supplement thereto) in accordance with the provisions of the Securities Act and with the securities or “blue sky” laws of the jurisdictions in which the Shares may be sold by the Investor, in connection with the offering
and sale of the shares of Common Stock and for such period of time thereafter as the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be delivered in connection with
sales of the shares of Common Stock. If during such period of time any event shall occur that in the judgment of the Company and its counsel is required to be set forth in the Registration Statement or the Prospectus or any Permitted Free Writing
Prospectus or should be set forth therein in order to make the statements made therein (in the case of the Prospectus, in light of the circumstances under which they were made) not misleading, or if it is necessary to amend the Registration
Statement or supplement or amend the Prospectus or any Permitted Free Writing Prospectus to comply with the Securities Act or any other applicable law or regulation, the Company shall forthwith prepare and, subject to Section 5.8 above, file
with the Commission an appropriate amendment to the Registration Statement or Prospectus Supplement to the Prospectus (or supplement to the Permitted Free Writing Prospectus) and shall expeditiously furnish or make available to the Investor an
electronic copy thereof. 
 Section 5.10 Selling Restrictions. 

(i) The Investor covenants that from and after the date hereof through and including the 90th day following the termination of this Agreement (the
“Restricted Period”), neither the Investor nor any of its affiliates (within the meaning of the Exchange Act), associates, agents or representatives nor any entity managed or controlled by the Investor shall, directly or indirectly, sell,
buy or trade any securities of the Company, except the shares of Common Stock issuable pursuant to this Agreement. During the Restricted Period, neither the Investor or any of its affiliates, associates, agents or representatives nor any entity
managed or controlled by the Investor shall, directly or indirectly, sell any shares of Common Stock of the Company it does not “own” or have the unconditional right to receive under the terms of this Agreement (within the meaning of Rule
200 of Regulation SHO promulgated by the Commission under the Exchange Act), including Put Shares and Commitment Shares in any account of the Investor or in any account directly or indirectly managed or controlled by the Investor or any of its
affiliates, associates, agents or representatives or any entity managed or controlled by the Investor. Without limiting the generality of the foregoing, prior to and during the Restricted Period, neither the Investor nor any of its affiliates,
associates, agents or representatives nor any entity managed or controlled by the Investor or any of its affiliates shall enter into a short position with respect to shares of Common Stock of the Company, including in any account of the
Investor’s or in any account directly or indirectly managed or controlled by the Investor or any of its affiliates, associates, agents or representatives or any entity managed or controlled by the Investor or any of its affiliates, except that
the Investor may sell Commitment Shares, as well as Put Shares that it is obligated to purchase under a pending Put Notice but has not yet taken possession of so long as the Investor (or the Broker-Dealer, as applicable) covers any such sales with
the Put Shares purchased pursuant to such Put Notice; provided, however, that the Investor (or the Broker-







 
Dealer, as applicable) shall not be required to cover any such sales with the Put Shares purchased pursuant to such Put Notice if (a) the Put Notice is terminated pursuant to a Cancellation
Notice from the Company to the Investor as provided herein or otherwise, by mutual agreement of the Company and the Investor and, as a result of such termination, no Put Shares are delivered to the Investor under this Agreement or (b) the
Company otherwise fails to deliver such Put Shares to the Investor on the applicable Closing Date upon the terms and subject to the provisions of this Agreement. Prior to and during the Restricted Period, the Investor or any of its affiliates,
associates, agents or representatives and any entity managed or controlled by the Investor shall not grant any option to purchase or acquire any right to dispose or otherwise dispose for value of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for, or warrants to purchase, any shares of Common Stock, or enter into any swap, hedge or other agreement that transfers, in whole or in part, the economic risk of ownership of the Common Stock,
except for such sales expressly permitted by this Section 5.10(i). 
 (ii) In addition to the foregoing, in connection with
any sale of the Company’s securities (including any sale permitted by paragraph (i) above), the Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements
of the Securities Act and the Exchange Act. 
 Section 5.11 Effective Registration Statement. During the Commitment Period,
the Company shall take all reasonable actions necessary to maintain the continuous effectiveness of the Registration Statement under the Securities Act. 
 Section 5.12 Non-Public Information. Neither the Company nor any of its directors, officers or agents shall disclose any material non-public information about the Company to the
Investor, unless a timely public announcement thereof is made by the Company in the manner contemplated by Regulation FD. 

Section 5.13 Broker/Dealer. The Investor covenants that it shall use one or more broker-dealers to effectuate all sales, if any, of
the Shares that it may purchase from the Company pursuant to this Agreement which (or whom) shall be unaffiliated with the Investor (the “Broker-Dealer”). The Investor shall provide the Company with all information regarding the
Broker-Dealer reasonably requested by the Company. The Investor shall be solely responsible for all fees and commissions of the Broker-Dealer, which shall not exceed customary brokerage fees and commissions. 

Section 5.14 Disclosure Schedule. 
 (i) During the Commitment Period, the Company shall from time to time update the Disclosure Schedule as may be required to satisfy the condition set forth in Section 6.4(i). For purposes of this
Section 5.14, any disclosure made in a schedule to the ClosingCertificate substantially in the form attached hereto as Exhibit C shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the
contrary, no update to the Disclosure Schedule pursuant to this Section 5.14 shall cure any previous breach of a representation or warranty of the Company contained in this Agreement and shall not affect any of the Investor’s rights or
remedies with respect to such previous breach. 
 (ii) Notwithstanding anything to the contrary contained in the Disclosure
Schedules or 







 
in this Agreement, the information and disclosure contained in any Schedule of the Disclosure Schedules shall be deemed to be disclosed and incorporated by reference in any other Schedule of the
Disclosure Schedules as though fully set forth in such Schedule for which applicability of such information and disclosure is readily apparent on its face. The fact that any item of information is disclosed in the Disclosure Schedules shall not be
construed to mean that such information is required to be disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and the thresholds (whether based on quantity, qualitative characterization, dollar amounts or
otherwise) set forth herein shall not be used as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this Agreement. 
 Section 5.15 Reservation of Common Stock. The Company will, from time to time as needed in advance of a Closing Date, reserve and keep available until the consummation of such Closing,
free of preemptive rights, sufficient shares of Common Stock for the purpose of enabling the Company to satisfy its obligation to issue the Put Shares to be issued in connection therewith. The number of shares so reserved from time to time, as
theretofore increased or reduced as hereinafter provided, may be reduced by the number of shares of Common Stock actually delivered hereunder. 
 ARTICLE VI 
 CONDITIONS TO THE PURCHASE AND SALE OF THE SHARES

 Section 6.1 Opinion of Counsel and Certificate. Simultaneously with the execution and delivery of this Agreement, the
Investor has received (i) an opinion of counsel to the Company, dated the Effective Date, in the form mutually agreed to by the parties hereto, and (ii) a certificate from the Company, dated the Effective Date, in the form of the
Compliance Certificate attached as Exhibit B hereto. 
 Section 6.2 Principal Market Regulation. The Company shall not
issue any Put Shares and the Investor shall not have the right to receive any Put Shares if the issuance of such shares would exceed the aggregate number of shares of Common Stock which the Company may issue without breaching the Company’s
obligations under the rules or regulations of the Principal Market (i.e., the shareholder approval requirements set forth in NASDAQ Listing Rule 5635) (the “Exchange Cap”), except that such limitation shall not apply in the event that the
Company obtains the approval of its stockholders as required by the applicable rules of the Principal Market for issuances of Common Stock in excess of such amount. Until such approval is obtained, Investor shall not be issued under the Transaction
Documents, shares of Common Stock in an amount greater than the Exchange Cap. 
 Section 6.3 Conditions Precedent to the Obligation
of the Company. The obligation hereunder of the Company to issue and sell the Put Shares to the Investor under any Put Notice is subject to the satisfaction or (to the extent permitted by applicable law) waiver of each of the conditions set
forth below. These conditions are for the Company’s sole benefit and (to the extent permitted by applicable law) may be waived by the Company at any time in its sole discretion. 







 (i) Accuracy of the Investor’s Representations and Warranties. The
representations and warranties of the Investor contained in this Agreement (a) that are not qualified by “materiality” shall have been true and correct in all material respects when made and shall be true and correct in all material
respects as of the applicable Put Date and the applicable Closing Date with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and
warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by “materiality” shall have been true and correct when made and shall be true and correct as of the applicable Put Date and
the applicable Closing Date with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of
such other date. 
 (ii) Performance by the Investor. The Investor shall have performed, satisfied and complied in
all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to the applicable Put Date and the applicable Closing Date. 

(iii) No Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by this Agreement. 

(iv) No Suspension, etc. Trading in the Common Stock shall not have been suspended by the Commission or the Principal
Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Put Date and applicable Closing Date), and, at any time prior to the applicable Put Date and
applicable Closing Date, none of the events described in clauses (i), (ii) and (iii) of Section 5.7 shall have occurred, trading in securities generally as reported on the Principal Market shall not have been suspended or limited nor
shall a banking moratorium have been declared either by the United States or New York State authorities. 
 (v) No
Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been
commenced or threatened, against the Company or any Subsidiary, or any of the officers, directors or affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change the transactions contemplated by this Agreement, or seeking
damages in connection with such transactions. 
 (vi) Limits. The issuance and sale of the Put Shares issuable
pursuant to such Put Notice shall not (A) exceed the Maximum Put Amount, or together with all other Put Notices the Maximum Commitment Amount or the Exchange Cap or (B) violate Section 5.5 hereof. 

(vii) Registration Statement. The Registration Statement is effective and neither the Company nor the Investor shall have
received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement. The Company shall have a maximum dollar amount certain of Common Stock registered under the Registration Statement








 
which are in an amount (a) as of the Effective Date, not less than the Maximum Commitment Amount and (b) as of the applicable Put Date, not less than the maximum dollar amount worth of
Put Shares issuable pursuant to the applicable Put Notice. The Current Report shall have been filed with the Commission, as required pursuant to this Agreement, and all Prospectus Supplements shall have been filed with the Commission, as required
pursuant to this Agreement, to disclose the sale of the Put Shares prior to the applicable Closing Date only as required by this Agreement, and an electronic copy of each such Prospectus Supplement together with the Base Prospectus shall have been
delivered or made available to the Investor in accordance with Section 5.9 hereof. Any other material required to be filed by the Company or any other offering participant pursuant to Rule 433(d) under the Securities Act shall have been filed
with the Commission within the applicable time periods prescribed for such filings by Rule 433 under the Securities Act. 
 Section 6.4
Conditions Precedent to the Obligation of the Investor. The obligation hereunder of the Investor to accept a Put Notice and to acquire and pay for the Put Shares is subject to the satisfaction or (to the extent permitted by applicable
law) waiver, at or before each Put Date and each Closing Date, of each of the conditions set forth below. These conditions are for the Investor’s sole benefit and (to the extent permitted by applicable law) may be waived by the Investor at any
time in its sole discretion. 
 (i) Accuracy of the Company’s Representations and Warranties. The
representations and warranties of the Company contained in this Agreement, as modified by the Disclosure Schedule, which may be updated pursuant to Section 5.14, (a) that are not qualified by “materiality” or “Material
Adverse Effect” shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the applicable Put Date and the applicable Closing Date with the same force and effect as if made
on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that are
qualified by “materiality” or “Material Adverse Effect” shall have been true and correct when made and shall be true and correct as of the applicable Put Date and the applicable Closing Date with the same force and effect as if
made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other date. 

(ii) Registration Statement. The Registration Statement is effective and neither the Company nor the Investor shall have
received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement. The Company shall have a maximum dollar amount certain of Common Stock registered under the Registration Statement which are
in an amount (a) as of the Effective Date, not less than the Maximum Commitment Amount and (b) as of the applicable Put Date, not less than the maximum dollar amount worth of Put Shares issuable pursuant to the applicable Put Notice. As of
the applicable Put Date and the applicable Closing Date, the Investor shall be permitted to utilize the Prospectus to resell all of the Commitment Shares and Put Shares it then owns or has the right to acquire pursuant to all Put Notices issued
pursuant to this Agreement. The Current Report shall have been filed with the Commission, as required pursuant to this Agreement, and all Prospectus Supplements shall have been filed with the Commission, as required pursuant to this Agreement, to
disclose the sale of the Put Shares prior to the applicable Closing Date only as required by this Agreement, and an 







 
electronic copy of each such Prospectus Supplement together with the Base Prospectus shall have been delivered or made available to the Investor in accordance with Section 5.9 hereof. Any
other material required to be filed by the Company or any other offering participant pursuant to Rule 433(d) under the Securities Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule
433 under the Securities Act. 
 (iii) No Suspension. Trading in the Common Stock shall not have been suspended by
the Commission or the Principal Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Put Date and applicable Closing Date), and the Company shall not
have received any notice that the listing or quotation of the Common Stock on the Principal Market shall be terminated on a date certain (which termination shall be final and non-appealable). At any time prior to the applicable Put Date and
applicable Closing Date, none of the events described in clauses (i), (ii) and (iii) of Section 5.7 shall have occurred, trading in securities generally as reported on the Principal Market shall not have been suspended or limited, nor
shall a banking moratorium have been declared either by the United States or New York State authorities. 
 (iv)
Performance of the Company. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the
Company at or prior to the applicable Put Date and the applicable Closing Date and shall have delivered to the Investor on the applicable Closing Date the Closing Certificate substantially in the form attached hereto as Exhibit C. 

(v) No Injunction. No statute, rule, regulation, order, decree, writ, ruling or injunction shall have been enacted,
entered, promulgated, threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by this Agreement.

 (vi) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or
governmental authority shall have been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been commenced or threatened, against the Company or any Subsidiary, or any of the officers, directors or
affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change the transactions contemplated by this Agreement, or seeking damages in connection with such transactions. 

(vii) Limits. The issuance and sale of the Put Shares issuable pursuant to such Put Notice shall not (A) exceed the
Maximum Put Amount, or together with all other Put Notices the Maximum Commitment Amount or the Exchange Cap or (B) violate Section 5.5 hereof. 
 (viii) Shares Authorized and Delivered. The Commitment Shares and the Put Shares issuable pursuant to each Put Notice shall have been duly authorized by all necessary corporate action of the
Company. The Company shall have delivered the Commitment Shares and all Shares relating to all prior Put Notices, as applicable. 
 (ix) Listing of Shares. If required, the Company shall have submitted to the Principal Market, at or prior to the applicable Put Date, a notification form of listing of additional shares
related to the Put Shares issuable pursuant to such Put Notice, in accordance with the bylaws, 







 
listed securities maintenance standards and other rules of the Principal Market and, prior to the applicable Closing Date, such Put Shares shall have been approved for listing or quotation on the
Principal Market (if such approval is required for the listing or quotation thereof on the Principal Market), subject only to notice of issuance. 
 (x) Opinions of Counsel; Bring-Down. Subsequent to the filing of the Current Report pursuant to Section 2.7 and prior to the first Put Date, the Investor shall have received an opinion
from counsel to the Company in the form mutually agreed to by the parties hereto. On each Closing Date, the Investor shall have received an opinion “bring down” from counsel to the Company in the form mutually agreed to by the parties
hereto. 
 (xi) Payment of Investor’s Counsel Fees; Due Diligence Expenses. On the Effective Date, the
Company shall have paid by wire transfer of immediately available funds to an account designated by the Investor’s counsel, the fees and expenses of the Investor’s counsel in accordance with Section 9.1 of this Agreement. 

ARTICLE VII 

TERMINATION 

Section 7.1 Term, Termination. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically upon the
earlier of the (i) expiration of the Commitment Period or (ii) the date that Put Shares totaling the Maximum Commitment Amount have been issued to the Invstor pursuant to this Agreement. Subject to Section 7.3, this Agreement may be
terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent, it being hereby acknowledged and agreed that the Investor may not consent
to such termination during a Pricing Period or prior to a Closing Date in the event the Investor has instructed the Broker-Dealer to effect an open-market sale of Put Shares which are subject to a pending Put Notice but which have not yet been
physically delivered by the Company (and/or credited by book-entry) to the Investor in accordance with the terms and subject to the conditions of this Agreement. Subject to Section 7.3, the Company may terminate this Agreement effective upon
one Trading Day’s prior written notice to the Investor delivered in accordance with Section 9.4; provided, however, that (i) such termination shall not occur during a Pricing Period or, subsequent to the issuance of a Put Notice,
prior to the Closing Date related to such Put Notice and (ii) prior to issuing any press release, or making any public statement or announcement, with respect to such termination, the Company shall consult with the Investor and shall obtain the
Investor’s consent to the form and substance of such press release or other disclosure, which consent shall not be unreasonably delayed or withheld. 
 Section 7.2 Other Termination. If the Company provides the Investor with an Other Financing Notice or an Integration Notice, in each case pursuant to Section 5.6(ii) of this
Agreement, or if the Company otherwise enters into any agreement, plan, arrangement or transaction with a third party or determines to utilize any existing agreement, plan or arrangement with a third party, in each case the principal purpose of
which is to implement, effect or consummate outside a Pricing Period, but otherwise during the Commitment Period, a Similar Financing, an ATM or a Price Reset Provision (in which case the Company shall so notify the Investor within 48 hours








 
thereof), then in all such cases, subject to Section 7.3, the Investor shall have the right to terminate this Agreement within the subsequent 30-day period (the “Event Period”),
effective upon one Trading Day’s prior written notice delivered to the Company in accordance with Section 9.4 at any time during the Event Period. The Company shall promptly (but in no event later than 24 hours) notify the Investor (and,
if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules and regulations of the Principal Market, the Company shall publicly disclose such information in accordance
with Regulation FD and the applicable rules and regulations of the Principal Market), and, subject to Section 7.3, the Investor shall have the right to terminate this Agreement at any time after receipt of such notification, if: (i) any
condition, occurrence, state of facts or event constituting a Material Adverse Effect has occurred; (ii) a Material Change in Ownership has occurred or the Company enters into a definitive agreement providing for a Material Change in Ownership;
or (iii) a default or event of default has occurred and is continuing under the terms of any agreement, contract, note or other instrument to which the Company or any of its Subsidiaries is a party with respect to any indebtedness for borrowed
money representing more than 10% of the Company’s consolidated assets, in any such case, upon one Trading Day’s prior written notice delivered to the Company in accordance with Section 9.4 hereof. 

Section 7.3 Effect of Termination. In the event of termination by the Company or the Investor pursuant to Section 7.1 or 7.2, as
applicable, written notice thereof shall forthwith be given to the other party as provided in Section 9.4 and the transactions contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is
terminated as provided in Section 7.1 or 7.2 herein, this Agreement shall become void and of no further force and effect, except that (i) the provisions of Article VIII (Indemnification), Section 9.1 (Fees and Expenses),
Section 9.2 (Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.9 (Survival), Section 9.11 (Publicity), Section 9.12 (Severability) and
this Article VII (Termination) shall remain in full force and effect notwithstanding such termination, (ii) if the Investor owns any Shares at the time of such termination, the covenants and agreements of the Company and the Investor, as
applicable, contained in Section 5.1 (Securities Compliance), Section 5.3 (Compliance with Laws), Section 5.7 (Stop Orders), Section 5.8 (Amendments to the Registration Statement; Prospectus Supplements; Free Writing
Prospectuses), Section 5.9 (Prospectus Delivery), Section 5.11 (Effective Registration Statement), Section 5.12 (Non-Public Information) and Section 5.13 (Broker/Dealer) shall remain in full force and effect notwithstanding such
termination for a period of six months following such termination, (iii) the covenants and agreements of the Investor contained in Section 5.10 (Selling Restrictions) shall remain in full force and effect notwithstanding such termination
for a period of 90 days following such termination, and (iv) if the Investor owns any Shares at the time of such termination, the covenants and agreements of the Company contained in Section 5.2 (Registration and Listing) shall remain in
full force and effect notwithstanding such termination for a period of 30 days following such termination. Notwithstanding anything in this Agreement to the contrary, no termination of this Agreement by any party shall affect any cash fees paid to
the Investor or its counsel pursuant to Section 9.1, in each case all of which fees shall be non-refundable, regardless of whether any Put Notices are issued by the Company or settled hereunder. Nothing in this Section 7.3 shall be deemed
to release the Company or the Investor from any liability for any breach under this Agreement, or to impair the rights of the Company and the Investor to compel specific performance by the other party of its obligations under this Agreement.








 ARTICLE VIII 
 INDEMNIFICATION 
 Section 8.1 General Indemnity. 

(a) Indemnification by the Company. The Company shall indemnify and hold harmless the Investor each affiliate, employee,
representative and advisor of and to the Investor, and each person, if any, who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act from and against all losses, claims, damages,
liabilities and expenses (including reasonable costs of defense and investigation and all attorneys’ fees) to which the Investor and each such other person may become subject, under the Securities Act or otherwise, insofar as such losses,
claims, damages, liabilities and expenses (or actions in respect thereof) arise out of or are based upon (a) any violation of United States federal or state securities laws or the rules and regulations of the Principal Market by the Company or
any of its Subsidiaries, affiliates, officers, directors or employees in connection with the transactions contemplated by this Agreement, (b) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by
reference, in the Registration Statement or any amendment thereto or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a material fact required to be stated therein or necessary to make the
statements therein not misleading, or (c) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference, in the Prospectus, any Issuer Free Writing Prospectus, or in any amendment thereof or
supplement thereto, or in any “issuer information” (as defined in Rule 433 under the Securities Act) of the Company, which “issuer information” is required to be, or is, filed with the Commission or otherwise contained in any
Free Writing Prospectus, or any amendment or supplement thereto, or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that (A) the Company shall not be liable under this Section 8.1(a) to the extent that a court of competent jurisdiction shall
have determined by a final judgment (from which no further appeals are available) that such loss, claim, damage, liability or expense resulted directly and solely from any such acts or failures to act, undertaken or omitted to be taken by the
Investor, any Broker Dealer or such person through its bad faith or willful misconduct, (B) the foregoing indemnity shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based
upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor expressly for use in a Current Report,
any Prospectus Supplement or any Permitted Free Writing Prospectus, or any amendment thereof or supplement thereto, and (C) with respect to the Prospectus, the foregoing indemnity shall not inure to the benefit of the Investor or any such
person from whom the person asserting any loss, claim, damage, liability or expense purchased Common Stock, if copies of all Prospectus Supplements required to be filed pursuant to Section 2.6 and 5.9, together with the Base Prospectus, were
timely delivered or made available to the Investor pursuant hereto and a copy of the Base Prospectus, together with a Prospectus Supplement (as applicable), was not sent or 







 
given by or on behalf of the Investor or any such person to such person, if required by law to have been delivered, at or prior to the written confirmation of the sale of the Common Stock to such
person, and if delivery of the Base Prospectus, together with a Prospectus Supplement (as applicable), would have cured the defect giving rise to such loss, claim, damage, liability or expense. 

Subject to Section 8.2, the Company shall reimburse the Investor and each such controlling person promptly upon demand (with
accompanying presentation of documentary evidence) for all legal and other costs and expenses reasonably incurred by the Investor or such indemnified persons in investigating, defending against, or preparing to defend against any such claim, action,
suit or proceeding with respect to which it is entitled to indemnification. 
 (b) Indemnification by the
Investor. The Investor shall indemnify and hold harmless the Company, each of its directors and officers, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20(a) of
the Exchange Act from and against all losses, claims, damages, liabilities and expenses (including reasonable costs of defense and investigation and all attorneys fees) to which the Company and each such other person may become subject, under the
Securities Act or otherwise, insofar as such losses, claims, damages, liabilities and expenses (or actions in respect thereof) arise out of or are based upon (i) any violation of law (including United States federal or state securities laws or
the rules and regulations of the Principal Market) by the Investor or the Broker-Dealer or any of their respective, affiliates, associates, representatives, agents, officers, directors or employees or any entity managed or controlled by the Investor
in connection with the transactions contemplated by this Agreement, (ii) any breach by the Investor of this Agreement, or (iii) any untrue statement or alleged untrue statement of a material fact contained in the Current Report or any
Prospectus Supplement or Permitted Free Writing Prospectus, or in any amendment thereof or supplement thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, in each case, to the extent, but only to the extent, the untrue statement, alleged untrue statement, omission or alleged omission was made in reliance upon, and in
conformity with, written information furnished by the Investor to the Company expressly for inclusion in the Current Report or such Prospectus Supplement or Permitted Free Writing Prospectus, or any amendment thereof or supplement thereto. Subject
to Section 8.2, the Investor shall reimburse the Company and each such director, officer or controlling person promptly upon demand for all legal and other costs and expenses reasonably incurred by the Company or such indemnified persons in
investigating, defending against, or preparing to defend against any such claim, action, suit or proceeding with respect to which it is entitled to indemnification. 
 Section 8.2 Indemnification Procedures. Promptly after a person receives notice of a claim or the commencement of an action for which the person intends to seek indemnification under
Section 8.1, the person will notify the indemnifying party in writing of the claim or commencement of the action, suit or proceeding; provided, however , that failure to notify the indemnifying party will not relieve the indemnifying party from
liability under Section 8.1, except to the extent it has been materially prejudiced by the failure to give notice. The indemnifying party will be entitled to participate in the defense of any claim, action, suit or proceeding as to which
indemnification is being sought, and if the indemnifying party 







 
acknowledges in writing the obligation to indemnify the party against whom the claim or action is brought, the indemnifying party may (but will not be required to) assume the defense against the
claim, action, suit or proceeding with counsel satisfactory to it. After an indemnifying party notifies an indemnified party that the indemnifying party wishes to assume the defense of a claim, action, suit or proceeding, the indemnifying party will
not be liable for any legal or other expenses incurred by the indemnified party in connection with the defense against the claim, action, suit or proceeding except that if, in the opinion of counsel to the indemnifying party, one or more of the
indemnified parties should be separately represented in connection with a claim, action, suit or proceeding, the indemnifying party will pay the reasonable fees and expenses of one separate counsel for the indemnified parties. Each indemnified
party, as a condition to receiving indemnification as provided in Section 8.1, will cooperate in all reasonable respects with the indemnifying party in the defense of any action or claim as to which indemnification is sought. No indemnifying
party will be liable for any settlement of any action effected without its prior written consent. Notwithstanding the foregoing sentence, if at any time an indemnified party that is entitled to reimbursement pursuant to this Article VIII shall have
requested (by written notice provided in accordance with Section 9.4) an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated hereby effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received
written notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of
such settlement. No indemnifying party will, without the prior written consent of the indemnified party, effect any settlement of a pending or threatened action with respect to which an indemnified party is, or is informed that it may be, made a
party and for which it would be entitled to indemnification, unless the settlement includes an unconditional release of the indemnified party from all liability and claims which are the subject matter of the pending or threatened action. 

If for any reason the indemnification provided for in this Agreement is not available to, or is not sufficient to hold harmless, an
indemnified party in respect of any loss or liability referred to in Section 8.1 as to which such indemnified party is entitled to indemnification thereunder, each indemnifying party shall, in lieu of indemnifying the indemnified party,
contribute to the amount paid or payable by the indemnified party as a result of such loss or liability, (i) in the proportion which is appropriate to reflect the relative benefits received by the indemnifying party, on the one hand, and by the
indemnified party, on the other hand, from the sale of Shares which is the subject of the claim, action, suit or proceeding which resulted in the loss or liability or (ii) if the allocation provided by clause (i) is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above, but also the relative fault of the indemnifying party, on the one hand, and the indemnified party, on the other
hand, with respect to the statements or omissions which are the subject of the claim, action, suit or proceeding that resulted in the loss or liability, as well as any other relevant equitable considerations. 

The remedies provided for in Section 8.1 and this Section 8.2 are not exclusive and shall not limit any rights or remedies
which may otherwise be available to any indemnified person at law or in equity. 







 ARTICLE IX 
 MISCELLANEOUS 
 Section 9.1 Fees and Expenses. Each party shall bear its
own fees and expenses related to the transactions contemplated by this Agreement; provided, however, that the Company has paid the Investor’s counsel, attorneys’ fees and expenses in the amount of $25,000 (inclusive of disbursements and
out-of-pocket expenses), in connection with the preparation, negotiation, execution and delivery of this Agreement, legal due diligence and all other related transaction matters. The Company shall pay all U.S. federal, state and local stamp and
other similar transfer and other taxes and duties levied in connection with issuance of the shares of Common Stock pursuant hereto. For the avoidance of doubt, all of the fees payable to the Investor or its counsel pursuant to this Section 9.1
shall be non-refundable, regardless of whether any Put Notices are issued by the Company or settled hereunder. In addition, upon the execution of this Agreement, the Company shall issue to the Investor the number of shares of Common Stock (the
“Commitment Shares”) equal to $500,000 divided by the average of the VWAP for the five Trading Days immediately preceding the Effective Date. 
 Section 9.2 Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial. 
 (i) The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific
terms or were otherwise breached. It is accordingly agreed that either party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to enforce specifically the terms
and provisions hereof this being in addition to any other remedy to which either party may be entitled by law or equity. 
 (ii)
Each of the Company and the Investor (a) hereby irrevocably submits to the jurisdiction of the courts of the State of New York in New York County or the court of the United States, Southern District of New York for the purposes of any suit,
action or proceeding arising out of or relating to this Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the
suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit, action or proceeding by mailing a
copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 9.2 shall affect or
limit any right to serve process in any other manner permitted by law. 
 (iii) EACH OF THE COMPANY AND THE INVESTOR
HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY 







 
PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER. 

Section 9.3 Entire Agreement; Amendment. This Agreement, together with the exhibits referred to herein and the Disclosure Schedule,
and the Confidentiality Agreement, dated as of April 23, 2012, by and between the Company and the Investor, represents the entire agreement of the parties with respect to the subject matter hereof and thereof, and there are no promises,
undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth herein or therein. No provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.
The Disclosure Schedule and all exhibits to this Agreement are hereby incorporated by reference in, and made a part of, this Agreement as if set forth in full herein. 
 Section 9.4 Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand
delivery or facsimile (with facsimile machine confirmation of delivery received) at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day
following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid,
addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The address for such communications shall be: 

If to the Company:
 Ebun S. Garner, Esq.

 General Counsel and SVP 
 Alphatec
Holdings, Inc. 
 5818 El Camino Real 

Carlsbad, CA 92008 
 Facsimile: 760-431-9083

 With a copy to: 
 Michael Fantozzi,
Esq. 
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 
 One Financial Center 
 Boston, MA02111 
 Facsimile: (617) 542-2241 
 If to Investor: 

Barry Patterson 
 Eclipse Advisors, LLC

 551 Fifth Avenue, 6th floor, suite 612 
 New York, NY 10176 
 Facsimile: (212) 409-8447 







 With a copy to: 
 Marc G. Rosenberg, Esq. 
 McLaughlin & Stern, LLP 

260 Madison Avenue 
 New York, NY 10016

 Facsimile: (800) 933-0981 

Either party hereto may from time to time change its address for notices by giving at least 10 days advance written notice of such changed address to the
other party hereto. 
 Section 9.5 Waivers. No waiver by either party of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provisions, condition or requirement hereof nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right accruing to it thereafter. No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. 

Section 9.6 Headings; Construction. The article, section and subsection headings in this Agreement are for convenience only and shall
not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms
“herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found. The parties agree that each of them and their respective counsel has
reviewed and had an opportunity to revise this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.
In addition, each and every reference to share prices and shares of Common Stock in this Agreement shall be subject to adjustment for any stock splits, stock combinations, stock dividends, recapitalizations and other similar transactions that occur
on or after the date of this Agreement. 
 Section 9.7 Successors and Assigns. The Investor may not assign this Agreement to
any person without the prior consent of the Company, in the Company’s sole discretion. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. The assignment by a party to this Agreement of
any rights hereunder shall not affect the obligations of such party under this Agreement. 
 Section 9.8 Governing Law. This
Agreement shall be governed by and construed in accordance with the internal procedural and substantive laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of the laws
of any other jurisdiction. 







 Section 9.9 Survival. The representations, warranties, covenants and agreements of the
Company and the Investor contained in this Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided , however , that (i) the provisions of Article VII (Termination), Article VIII
(Indemnification), Section 9.1 (Fees and Expenses), Section 9.2 (Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.11 (Publicity),
Section 9.12 (Severability) and this Section 9.9 (Survival) shall remain in full force and effect notwithstanding such termination, (ii) if the Investor owns any Shares at the time of such termination, the covenants and agreements of
the Company and the Investor, as applicable, contained in Section 5.1 (Securities Compliance), Section 5.3 (Compliance with Laws), Section 5.7 (Stop Orders), Section 5.8 (Amendments to the Registration Statement; Prospectus
Supplements; Free Writing Prospectuses), Section 5.9 (Prospectus Delivery), Section 5.11 (Effective Registration Statement), Section 5.12 (Non-Public Information) and Section 5.13 (Broker/Dealer) shall remain in full force and
effect notwithstanding such termination for a period of six months following such termination, (iii) the covenants and agreements of the Investor contained in Section 5.10 (Selling Restrictions) shall remain in full force and effect
notwithstanding such termination for a period of 90 days following such termination, and (iv) if the Investor owns any Shares at the time of such termination, the covenants and agreements of the Company contained in Section 5.2
(Registration and Listing) shall remain in full force and effect notwithstanding such termination for a period of 30 days following such termination. 
 Section 9.10 Counterparts. This Agreement may be executed in counterparts, all of which taken together shall constitute one and the same original and binding instrument and shall become
effective when all counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties hereto need not sign the same counterpart. In the event any signature is delivered by facsimile, digital
or electronic transmission, such transmission shall constitute delivery of the manually executed original. 
 Section 9.11
Publicity. On or after the Effective Date, the Company may issue a press release or otherwise make a public statement or announcement with respect to this Agreement or the transactions contemplated hereby or the existence of this
Agreement (including, without limitation, by filing a copy of this Agreement with the Commission); provided, however, that prior to issuing any such press release, or making any such public statement or announcement, the Company shall consult with
the Investor on the form and substance of such press release or other disclosure (unless the disclosure previously has been reviewed and approved by the Investor). 
 Section 9.12 Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the
provisions or part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a
provision of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and
enforceable to the maximum extent possible. 







 Section 9.13 No Third Party Beneficiaries. Except as expressly provided in Article VIII,
this Agreement is intended only for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 

Section 9.14 Further Assurances. From and after the date of this Agreement, upon the request of the Investor or the Company, each of
the Company and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement. 

[The remainder of this page is intentionally left blank.] 







 IN WITNESS WHEREOF, the parties hereto have caused this Investment Agreement to be
executed by the undersigned, thereunto duly authorized, as of the date first set forth above. 
  

			
	ALPHATEC HOLDINGS, INC.
		
	By:	 	 /s/ Leslie Cross

	Name: Leslie Cross
	Title: Chairman and CEO
	
	ECLIPSE ADVISORS, LLC
		
	By:	 	 /s/ Barry Patterson

	Name: Barry Patterson
	Title: Managing Member